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Endometrial Cancer (EC) is the most common gynaecologic malignancy in the developed 
world, and in Aotearoa New Zealand, incidence is increasing in premenopausal women. The 
Levonorgestrel Intrauterine System (LNG-IUS), also known as Mirena®, is gaining traction as 
an alternative treatment for hyperplasia and early stage EC for women wanting to retain their 
fertility, or who are unable to undergo surgery. However, 30 to 50% of women do not respond 
to treatment, and the mechanisms for resistance are not understood. The aim of this project was 
to investigate predictive biomarkers for Mirena® treatment of early stage endometrial cancer. 
 
Two levonorgestrel (LNG) resistant endometrial cancer cell lines (MFE296R and MFE319R) 
and cultures from three early stage endometrial cancer patients (GB#13, GB#16, GB#23) were 
developed. A literature search was conducted to identify possible candidate biomarkers of LNG 
resistance. RT-qPCR was used to analyse the relative mRNA expression of 15 candidate 
biomarkers from MFE296R and MFE319R. mRNA expression of the top six differentially 
expressed genes was then measured in primary cultures. The behavioural profile of MFE296R 
and MFE319R were analysed using proliferation, adhesion, migration (wound healing and 
transwell) and invasion (spheroid) assays. 
 
Relative mRNA expression of CRISPLD1, KLF4, SATB2, SOX17, ANO1 and HE4 were 
significantly amplified in MFE296R and MFE319R cells compared to their LNG sensitive 
clones. Relative mRNA expression of SOX17, ANO1, SATB2, KLF4 and ER in the GB#13R 
cell line was increased compared to the GB#13S cells. In the GB#16R cell line, results show 
increased relative mRNA expression of ANO1, SATB2, KLF4, CRISPLD1 and HE4 compared 
to the GB#16S cells. Relative mRNA expression of SOX17, KLF4, ER, CRISPLD1 and HE4 
in the GB#23R cell line was increased compared to the GB#23S cells. LNG resistance had no 
effect on proliferation however significantly increased transwell migration in MFE319R cells 
(p=0.03), decreased cellular invasion in MFE296R cells, and decreased cellular adhesion to 
collagen in MFE29R cells (p=0.012) and MFE319R cells (p=0.04). 
 
Relative expression of CRISPLD1, KLF4, SATB2, SOX17, ANO1 and HE4 were significantly 
upregulated in resistant immortalised cell lines. This study suggests that these genes may serve 
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Chapter 1: Introduction  
1.1 Endometrial cancer incidence, aetiology and precursors 
1.1.1 Incidence 
Endometrial cancer (EC) is the most common gynaecologic malignancy in the developed world 
contributing to 3.9% of total cancers in women 1. Currently, EC is the 14th most common cause 
of mortality across all cancers 1. In Aotearoa New Zealand (NZ), approximately 400 women 
are diagnosed with EC annually, making it the fifth most common cancer in women nationwide. 
The majority of these women are between the ages of 45 and 64 2,  however, incidence is 
increasing in premenopausal women, particularly in Māori and Pasifika populations 3. 
Currently, 5% of diagnosed women are under the age of 40 3, 4.  
1.1.2 Aetiology 
The aetiology of EC is multifactorial; EC is mainly a hormone-driven cancer with 80% of 
cancers induced by oestrogen domination or attenuation of progesterone 5. Physiologically, 
oestrogen signalling is regulated via progesterone, hence, the absence of progesterone leads to 
an excess of oestrogenic signalling resulting in a hyperplastic, thickened state of the 
endometrium 5.  
Over 40% of EC cases can be attributed to environmental, non-genetic risk factors such as 
obesity and lack of physical activity 3, 6, 7. Women with a higher Body Mass Index (BMI 
>40kg/m2) have a seven fold increased risk of EC in comparison to women with a BMI within 
the healthy range (BMI 18.5-25kg/m2) 8. Adipocytes in adipose tissue produce aromatase, an 
enzyme responsible for converting androgens to estrone and estradiol 9-11. Therefore, carrying 
excess adipose tissue leads to >40% increased circulating estrone and estradiol increasing the 
risk of endometrial hyperplasia (precursor) in comparison to women with a normal BMI 9-12.  
Early age at menarche, later age of menopause and anovulation can all attenuate physiological 
progesterone circulation, also contributing to the risk of EC 5, 9, 13. Tamoxifen use for treatment 
of breast cancer has proven to increase risk of EC, as tamoxifen is an oestrogen antagonist in 
the breast tissue, but an oestrogen agonist in the endometrial tissue, leading to increased 
exogenous oestrogen exposure and subsequent cancer 14. Lynch Syndrome (LS) is caused by a 
germline mutation in one of many mismatch repair genes. Individuals that carry this genetic 
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burden have an increased risk of developing several cancers including EC 15 where women with 
LS account for up to 5% of cases 15.                                     
1.1.3 Precursors: endometrial hyperplasia  
Endometrial hyperplasia is the abnormal, non-invasive proliferation of the endometrial tissue 
as a result of excess oestrogenic stimulation, constituting a precancerous state of the uterus 16-
20.  All forms of hyperplasia share mutual morphological changes such as an increase in the 
gland-stroma ratio, and irregularity in both gland shape and size 19. The World Health 
Organisation classifies endometrial hyperplasia firstly into hyperplasia with atypia, and 
hyperplasia without atypia. 19.  
The most common clinical presentation of endometrial hyperplasia is menorrhagia (heavy 
bleeding) followed by postmenopausal bleeding 21. Notably, a high proportion of women with 
endometrial hyperplasia are premenopausal 21 in comparison to EC, which more commonly 
affects post-menopausal women 22. Younger premenopausal women diagnosed with 
endometrial hyperplasia typically present with polycystic ovarian syndrome (PCOS) 23 which 
results in unopposed oestrogen stimulation during anovulatory periods leading to increased 
cellular proliferation 23. Younger women also commonly present with increased oestrogen 
levels as a result of increased BMI 23.  
1.1.4 Endometrial hyperplasia progression 
Atypical hyperplasia is identified as the most significant prognostic factor that determines 
progression into malignancy 17, 24. Non atypical hyperplasia is not associated with being a 
precursor to EC and is largely self-limited 17, 25.  
Progression of atypical hyperplasia into EC has been reported at rates from 10% 26 to 23% 17 
and up to 52% 25 in the absence of treatment. While the sustained exposure to unopposed 
exogenous or endogenous oestrogen is attributed to endometrial hyperplasia progression 23, 27, 
there is a myriad of irregularities implicated in the carcinogenic progression of endometrial 
hyperplasia into EC (Figure 1). Type I EC is related to hyperestrogenism associated with 
endometrial hyperplasia into EC alongside amplified oestrogen/progesterone receptor 
expression in younger women 28, 29. 30 Type II endometrial cancer often arises in endometrial 






Figure 1: Pathway of endometrial cancer hyperplasia to endometrial cancer and the genetic 
disruptions associated with progression adapted from 32. Made by Dolly Dore. 
Hyper methylation of PTEN and MLH1 alongside increased oestrogen exposure have been implicated in the 
progression of a normal uterus into endometrial hyperplasia. 10-50% of endometrial hyperplasia cases will 
progress into type I EC. MHL-1, PTEN and k-RAS mutations have been implicated in the progression of hyperplasia 
to type I EC. Mutations in HER2/neu, p53, p16 and E-cadherin have been associated with the development of 
type II EC, which occurs independently of endometrial hyperplasia.   
1.2 Endometrial cancer classification  
1.2.1 Histological subtypes  
Traditionally, EC has been classified into two subtypes known as Bokham type I and type II 33 
based on histological characteristics, oestrogen/progesterone receptor expression and cancer 
grade 33 (Table 1). Approximately 75% of ECs are type I which are low grade, endometrioid, 
diploid, hormone-receptor-positive cancers that are associated with a good prognosis and 5-
year survival of >80% 34-36. Women with Type I lesions often present with anovulatory 
bleeding, infertility (in pre-menopausal cases), obesity, hyperlipidaemia and associated 
metabolic disturbances 33. These tumours exhibit superficial myometrium invasion, and are 
highly sensitive to synthetic progesterone intervention due to their positive hormone receptor 
status 33, 37, 38.  
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Type II EC forms a range of poorly differentiated non-endometrioid adenocarcinomas 
exhibiting high-grade aneuploidy 31, 33. Unlike type I carcinomas, type II EC most commonly 
arises in the setting of endometrial atrophy 22, 31. While type II cancers contribute to only about 
10% of EC incidence, they present at advanced stages showing many signs of clinical 
aggression and cause approximately 50% of EC related recurrence and death, with a low 5-year 
survival rate of 35% 31, 39 (Table 1). 
 
Table 1: Characteristics of type I and type II EC.  
EIC = endometrial intraepithelial carcinoma. Created by Molly Dore 
 
1.2.2 Molecular subtypes 
The molecular classification of EC in clinical practice is yet to be released however, the 
Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) guidelines have been 
developed to aid the integration of molecular subtype of EC and treatment planning(Figure 2). 
 TYPE I EC TYPE II EC 




Histology of adjacent 
endometrium 
Hyperplastic Atrophic 
Precursor lesion  Atypical hyperplasia  EIC  
Association with obesity yes no 
Histological subtype  Endometrioid  Serous/clear-
cell/mucinous/High-
grade endometrioid 
Clinical behaviour  Indolent Aggressive 






Diagnosis Early  Advanced stage (60%)  
Disrupted pathways  PIK3CA(90% of lesions), 
KRAS (20% of lesions), 
PTEN, ARID1 




Incorporation of these subtypes is important in consideration of conservative management of 
atypical hyperplasia and EC 40.  
The Cancer Genome Atlas (TCGA) classifies EC as POLE, microsatellite instability (MSI) 
hyper-mutated, copy-number-low and copy-number-high subtypes 22, 41, further described in 
Table 2 42. These classifications are based on whole genome sequencing which is not practical 
in a clinical setting therefore the ProMisE classification stratifies EC into p53 wild type/ 
nonspecific molecular profile (p53wt/NSM), replacing CN low, p53 abnormal (p53abn) 
replacing CN high, MMR defective (MMR-D) replacing MSI, POLE exonuclease domain 
mutant (POLE EDM) replacing POLE ultramutated, based of 3 immunohistochemical stains. 
Survival analysis comparison of ProMisE and TCGA subtypes demonstrated that the two mirror 
one another 40 (Figure 2). 
 
Table 2: Characteristics of the molecular subtypes of EC according to TCGA. Adapted from: 43. Created 
By Molly Dore. SCNAs = somatic copy number alterations, MSS = microsatellite stable, CN low = copy number 






































Figure 2: Characteristics of the molecular subtypes of EC according to the ProMisE guidelines. Figure 
made by Molly Dore taken from 40. 
 
1.3 Endometrial hyperplasia and cancer management 
1.3.1 Management of hyperplasia 
Difficulty surrounds differential diagnosis of atypical hyperplasia and well-differentiated EC 19 
and studies have failed to demonstrate reproducible molecular and histopathological differences 
between the two. Due to this, the standard for validation between atypical hyperplasia and EC 
is usually assessed following a hysterectomy 44-47.  
Low dose progestin is the gold standard treatment for hyperplasia 48. For atypical hyperplasia, 
pre-menopausal women are treated via high dose progestin therapy. Currently, the only 
treatment option for post-menopausal women with atypical hyperplasia and for women who do 
not respond to progestin treatment is a total hysterectomy 48. Current evidence is that both 
continuous oral and local intrauterine (Mirena®) progestogens are effective in achieving the 
regression of endometrial hyperplasia without atypia. However, the Mirena® should be the 
first-line medical treatment because compared with oral progestogens it has a higher disease 
regression rate with a more favourable bleeding profile and it is associated with fewer adverse 
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effects 49. However, at this stage, the absence of predictive biomarkers limits the certainty of 
recommendation 50, 51. 
Systemic progestogen therapy, such as medroxyprogesterone acetate (MPA), is efficacious in 
the treatment of hormone-sensitive hyperplasia and tumours 52, however, progesterone 
receptors are often downregulated on hyperplastic and cancerous cells, giving rise to a relatively 
short therapeutic duration 53. Systemic progestogen therapy has been successful in treating EC 
and more so hyperplasia, however, has low compliance rates due to adverse systemic effects 
including nausea, weight gain, abnormal vaginal bleeding 54 and increased risk of breast cancer 
55. Women treated solely on a hormonal basis are advised to be monitored via invasive 
endometrial biopsies (pipelles) every 3-6 months 53.  
1.3.2 Management of early-stage cancer   
The standard of care for early-stage EC in medically operable women consists of a 
hysterectomy with the addition of the surgical removal of both ovaries (Bilateral Salpingo-
Oophorectomy; BSO) and pelvic lymphadenectomy which forms the basis of surgical staging 
53, 56. A BSO is not ideal for pre-menopausal women as it results in surgical menopause, putting 
women at risk of long term oestrogen deprivation 57, which can result in significant cognitive, 
urogenital and skeletal effects 58. In cases where surgery is not curative, adjuvant therapy in the 
form of chemotherapy and/or radiation therapy is used to treat disease 59.  
Clinicians utilise the 2009 International Federation of Gynaecologists and Obstetricians (FIGO) 
surgical staging system in the management of EC patients (Figure 3) 60-62. Most diagnoses 
(70%) are made at early stages (stage I-II), which are associated with a positive prognosis and 
overall 5-year survival of almost 90%. Stage III and stage IV disease have respective survival 
rates of 60% and 20% and 30% 61. These stages make up 30% of initial diagnoses 61 .  
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Figure 3: FIGO Surgical Staging System. Adapted from: 60, 61. Made by Molly Dore.  
 
1.3.3 Adjuvant therapy 
In cases where surgery is not curative, adjuvant therapy is used to treat disease 59. The process 
of choosing suitable adjuvant therapy for EC stage 1B and more advanced disease is 
problematic. The most commonly considered adjuvant therapy is Radiotherapy (RT), often in 
the form of brachytherapy due to the radiosensitive nature of EC 63. Chemotherapy has not been 
well researched in early stage EC and no compelling evidence exists for or against 
chemotherapy as of now 64. Leon-Castillo et al., investigated the implication of EC molecular 
subtypes when using adjuvant therapy (chemotherapy and RT). This study found that the 5 year 
recurrence free survival for patients with p53abn EC was 48%, 98% for POLE EDM EC, 72% 
for MMR-D EC, and 74% for no specific molecular profile (NSMP) EC. When comparing 
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systemic chemotherapy and radiation therapy with radiation therapy alone the 5 year recurrence 
free survival for p53abn EC was 59% versus 36%, 100% versus 97% for patients 
with POLEmut EC, 68% versus 76% for MMR-D EC, and 80% versus 68% for NSMP EC. 
Molecular classification therefore has a strong prognostic value in high risk EC and should be 
incorporated into the treatment plans for patients.  
1.3.4 Comorbidities preventing surgery  
Individuals with a higher BMI are more likely to be burdened with comorbidities that can 
complicate primary surgery 5, 65. Higher BMI complicates the surgical approach due to 
associated comorbidities such as cardiovascular disease, obesity-hypoventilation syndrome and 
diabetes-related organ damage. This leads to 10% of women with obesity being deemed 
inoperable 66, despite this population being more likely to be diagnosed with suspected 
endometrial malignancy 67. Alongside comorbidities, women with obesity are physically more 
difficult to operate on due to decreased visualization of the pelvic region as a result of excess 
intraperitoneal fat and redundant bowel lying in the operative field 68. This leads to increased 
entry attempts for hysterectomy, increased difficulty in identification of landmarks and a 
reduction in successful completions of the surgery 69. Postoperative complications are more 
commonly observed in women with obesity. These include bowel and urologic complications, 
blood vessel injuries, pelvic hematoma, pelvic infection, pneumonia, increased blood loss, 
wound complications, and venous thromboembolisms 65, 67. In cases where disease is confined 
to the uterus and women are not suitable for primary surgery or desire a fertility sparing 









Figure 4: Treatment pathway for EC confined to the uterus.  





1.3.5 The Mirena® as a therapeutic option  
The LNG-IUS also known as Mirena®, is a long acting reversible contraception option for 
women. It is 99.9% effective in this role and works for up to 5 years 70. The Mirena® delivers 
levonorgestrel (LNG) directly to the uterus and is associated with a minor systemic adverse 
effect profile including bleeding irregularities, absence of menstruation (amenorrhoea), 
hormonal effects and weight gain, which are not associated with significant rates of suspension 
or noncompliance to treatment 71, 72. The Mirena® does not interfere with concurrent 
medications, and there is no evidence that treatment increases tubal infertility 73, which is 
important in women who desire to become pregnant at a later time.  
The Mirena® is also used to treat women with abnormal and heavy bleeding (menorrhagia) as 
LNG suppresses endometrial proliferation through counteracting the effect of oestrogen, 
producing endometrial atrophy due to decidualization and suppression of the endometrial 
glands 70. Furthermore, the Mirena® is gaining traction as an alternative treatment for 
hyperplasia and early stage EC for those women who are inoperable. The evidence base for the 
use of the Mirena® in this setting appears promising.  
1.3.5.1 The use of the Mirena® to treat endometrial hyperplasia  
Many studies have identified the Mirena® as an effective treatment of endometrial hyperplasia, 
with all of these studies yielding high response rates 74-80.  For example, in 2018 Varma et al., 
conducted a retrospective study in Birmingham and found that 90% of English women with 
endometrial hyperplasia (94/105) responded to Mirena® treatment and exhibited endometrial 
regression 81. Also notable is that 96% of these individuals achieved a significant level of 
regression after only one year 81. Complete response was identified as no presence of cancer or 
atypical hyperplasia in biopsies collected at the culmination of the trial 82. In a 2018 
retrospective study, Pal et al., showed a complete response rate of 75% (11/15) in American 
women with hyperplasia. Behrouzi et al., in a 2020 prospective trial observed a complete 
response in 83% (25/30) of women treated for atypical hyperplasia over the course of 12 
months.  
1.3.5.2 The use of the Mirena® to treat EC 
Fewer studies have investigated the efficacy of the Mirena® for the treatment of EC, however, 
the evidence also appears promising. In the same study conducted by Pal et al., women with 
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stage I EC showed high response rates (67%), alongside women with stage 2 EC (75%) 71. 
These women demonstrated a positive response, showing regression of cancer into hyperplasia 
However, the findings of this study need to be interpreted cautiously, due to higher than 
expected results possibly being associated with careful selection of women for conservative 
therapy, and results may have been subjected to bias intrinsic to retrospective studies 71.   
Behrouzi et al., in a 2020 prospective trial observed a complete response in 56% (12/27) of 
women treated for early stage EC over the course of 12 months. Westin et al., in a recent 2020 
prospective study observed a 66.7% response rate for early stage EC 83. This study however, 
only investigated 21 cases of early stage EC. A larger 2020 prospective trial (feMMe Trial) of 
165 women conducted by Obermair et al in Australia noted 52% complete response rate in 
women with early stage EC. A complete response was described as no cancer or hyperplasia 
with atypia present in a biopsy. Complete response was seen in 61% of the Mirena® only arm, 
57% of the Mirena® + Metformin arm and 67% of the Mirena® + weight-loss arm. This 
information has been shared in the 2020 patient and community symposium for the Queensland 
centre for Gynaecological Cancer Research but has yet to be published.  
More robust evaluations regarding the efficacy of Mirena® using prospective studies designed 
with increased power (i.e. larger sample size) and longer follow-up time-frames are needed. 
Such an approach would help mitigate potentially ambiguous findings that are associated with 
small sample sized studies. For example, a 2017 retrospective study conducted by Baker et al., 
observed a significantly lower (38%) response rate in women with EC than previously 
mentioned studies, had a small sample size of 16 women 84.  
1.3.5.3 The Mirena® vs systemic progestin therapy 
With regards to the comparison of systemic progestin therapy and Mirena® treatment, a 
systematic and meta-analysis of 24 studies including 1001 women conducted by Gallos et al., 
showed that Mirena® treatment had a higher pooled regression rate in both complex 
hyperplasia and atypical hyperplasia than oral progestogen treatment 85. A long term 
comparative cohort study of 334 women showed 94% of women treated with the Mirena® 
exhibited a regression of hyperplasia compared to 84% in women treated with oral progesterone 
74. The findings from this study also showed significantly lower hysterectomy rates in the 
women treated with the Mirena®, when compared to women treated with oral progesterone 74. 
Orbo et al., showed similar results in a multicentre control trial where 100% (53/53) of women 
treated with the Mirena® for hyperplasia showed a regular proliferative endometrium compared 
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to 96% of women treated with oral progesterone 80. As this was an observational study, residual 
confounding from unmeasurable variables were not accounted for, and therefore the results as 
presented likely show an augmented effect.  Finally, evidence from a meta-analysis of 7 
randomised control trials also concluded that for treatment of non-atypical endometrial 
hyperplasia, the Mirena® achieves significantly higher therapeutic effect rates and lower 
hysterectomy rates than oral progestin and should be offered as an alternative to oral progestin 
in these cases 86. The use of the Mirena® to treat EC has yet to be compared to the standardised 
treatment of systemic progesterone therapy.  
1.3.5.4 Risk of Mirena® use compared to surgery  
The risk-benefit ration of Mirena® treatment prior to hysterectomy is acceptable, and therefore, 
the option of managing EC conservatively in this window is able to be explored safely 87. Baker 
et al., showed a 6% progression rate for early stage EC in women treated with the Mirena® 84. 
Westin et al., observed recurrence in 9.5% of cancers following an initial response to the 
Mirena® 88. These recurrence rates are similar to what is seen in surgical management of 
endometrial hyperplasia and EC. Malzoni et al., observed a recurrence rate of 10.1% in patients 
managed with laparoscopic and laparotomic surgeries. Similarly, Obermair et al., observed a 
recurrence rate of 9% in patients who underwent a hysterectomy for EC 89. Posczaski et al., 
observed a higher recurrence rate of 17% in 300 women who underwent hysterectomy, 
specifically for early stage EC 90. Limited information is available about the recurrence rates of 
early stage EC following treatment with Mirena. More studies are beginning to incorporate this 
into their prospective design such as the feMMe trial and a phase II study of the Mirena® to 
treat hyperplasia and early stage EC by Minig et al., that will investigate the recurrence of 
hyperplasia and EC over 5 years (ClinicalTrials.gov Identifier: NCT00788671).  
The use of the Mirena® to treat hyperplasia and early stage EC has yet to be equivocally 
determined – and importantly, evidence appears that it there is recalcitrance in response to 
hyperplasia and early stage EC for some women – the reasons for which are not well 
understood. As response is not absolute, for women whom surgery isn’t an option, treatment 
with the Mirena® still carries a risk of failure. In order to better tailour treatment with the 
Mirena®, predictive biomarkers would need to be established and utilised clinically to 
determine non-responders prior to treatment. This should aid in guiding treatment from invasive 
to conservative approaches in women when it is possible and safe. 
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1.4 Predictive biomarkers for Mirena® treatment  
A 2016 qualitative study asked 786 people what their most pressing questions are for EC 
research. One of the top ten research questions for EC that emerged from broad-based 
engagement is “can we predict at the time of diagnosis which EC cases and precancerous lesions 
will respond to treatments?” 91. Currently, there are still no clinical biomarkers to predict the 
response to the Mirena®.   
While the Mirena® remains an option for the treatment of early-stage EC and hyperplasia, 30% 
of women treated this way still show disease progression 92. Differing responses associated with 
Mirena® treatment stems from the functional and phenotypic diversity observed in cancer cells, 
creating obstacles in clinical diagnosis and response to therapy. The degree of spatial diversity 
within an individual’s tumour is highly variable 93. This drives phenotypic variation, thus, 
posing a significant challenge to the diagnosis, management and treatment of cancer, alongside 
contributing to significant challenges when identifying biomarkers to guide clinical decision-
making in cancer medicine 94.   
Surgery has been proven to be associated with a high cure rate and low morbidity rate when 
treating EC, particularly in early stages 95. Because of this, predictive biomarkers would ensure 
that women are not exposed to further risk through the use of conservative Mirena® treatment 
instead of surgery. If that risk could be eliminated, then the Mirena® may not only be an option 
for inoperable women, but for all women who wish to preserve their uterus. 
1.4.1 Biomarkers for Mirena® treatment of endometrial hyperplasia and 
cancer 
While research has been conducted, few papers investigate biomarkers involved in LNG 
resistance explicitly, with only 3 looking at the effects of the Mirena® on EC cells.  These 
studies do however yield possible predictive biomarkers that should be investigated in auxiliary 
studies with larger samples sizes and multiple cell lines. The following discussion includes 
possible biomarkers with no predictive value, conflicting value and hormonal related effects.  
The majority of studies demonstrate no association with protein levels of Pax-2 96, Bcl-2 96, 97, 
COX-1 or MLH1 97 determined through immunohistochemistry (ICH). On a gross level, Pal et 
al., identified in their studies that increased uterine size is not associated with non-response to 
the Mirena®, and no significant association was found between BMI and non-response 71. The 
prospect of PTEN serving as a genetic predictive biomarker has produced conflicting results, 
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with Travaglino et al., showing PTEN has no predictive value in the context of progestin 
treatment through a systematic review of seven studies 98. However Janzen et al., observed in 
a mouse model, that low expression of PTEN alongside PR and KRAS activation could predict 
a negative response to progesterone treatment 99. In saying this, a study conducted on mice, 
may not be as generalizable as a study carried out with samples taken from women with EC, 
but these makers should be further researched using human samples.  
1.4.1.3 Potential hormonal biomarkers 
Poor oestrogen (ER) and progesterone receptor (PR) expression is shown to be associated with 
persistence/progression of EC however the same observation is not witnessed in women with 
atypical hyperplasia 97. Low expression of progesterone receptor protein has been previously 
associated with a poorer response to progesterone treatment 96, 97, 99-101. While most current 
studies associate this remark with systemic progestogen treatment, Reyes et al., observes the 
same in patients treated with the Mirena® 102 and also showed a relationship between 
progesterone receptor expression and FOXO1 mRNA expression, identifying FOXO1 to be a 
potential predictive marker to Mirena® treatment 102. While this study 102 gains credibility from 
using biopsy specimens from LNG treated women, and performing both IHC and quantitative 
polymerase chain reaction (qPCR), it is important to note that the results observed are from 10 
women only, making it relatively non-generalisable. The oestrogen receptor has also been 
investigated as a potential biomarker, with current research showing increased expression of 
ERα and mRNA expression of the ESR1 gene predicts a negative response to progesterone 
treatment, with Akesson et al., observing higher ER protein levels specifically in non-
responders treated with the Mirena® 100. Again, the cohort size for Akesson et al., study is 
small, and additional studies should be carried out on larger sample sizes 100.  
ARID1A knockout has been seen to promote primary resistance to progesterone (MPA) 
treatment via downregulation of progesterone receptor B (PRB) in EC cells, meaning it could 
serve as a potential predictive marker to Mirena® treatment of EC 103. At this stage, baseline 
and post-treatment mRNA levels of ARID1A have only been investigated in one cell line, 
leaving validation room for new studies to be carried out on human samples and primary cell 
lines.  
The HOTAIR gene has been implicated in the enhancement of sensitivity to progesterone in EC 
104. This is proven to be through epigenetic regulation of PRB. HOTAIR was found to be 
inversely related to PRB expression, therefore, knockdown of HOTAIR promotes PRB 
expression which promotes sensitivity of progesterone treatment 104. So far, HOTAIR has only 
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been implicated in the progesterone resistance mechanism, therefore, future studies should look 
at the differences in HOTAIR expression between progesterone resistant and sensitive cells or 
in clinical cohorts in order to be able to identify this as a predictive biomarker. 
1.4.1.4 Potential non-hormonal biomarkers 
Tumour suppressor p53 has been studied as a potential biomarker; one study carried out on 50 
hyperplastic patient samples showed that decreased p53 protein expression may be a predictive 
biomarker of progestin resistance 101. Patients that failed to respond to progesterone therapy 
had significantly lower p53 levels than those that showed regression of hyperplasia. However, 
this is only noted in women with atypical hyperplasia and EC, and these observations were 
made following six months of treatment. Baseline recordings would be needed to support the 
claim of p53 acting as a potential predictive marker.   
Baseline serum HE4 has been investigated as a potential biomarker to monitor the efficacy of 
the Mirena® in atypical hyperplasia and early-stage EC 105. It is suggested that higher levels of 
serum HE4 during and following treatment indicate a negative response to treatment in early 
stage EC and atypical hyperplasia. This study observes a significant reduction in HE4 from 
baseline after three months of Mirena® treatment and no significant changes are seen in 
responders.  Due to this study relying on baseline HE4 serum readings, supplementary studies 
conducted on these readings should use larger populations as it would aid in determining 
accurate HE4 serum cut-offs for response vs non-response to confirm the findings from this 
study 105. Orbo et al.,  conducted a multicentre randomized control trial studying HE4 in relation 
to progesterone treatment, both MPA and Mirena®, and found that an increase in the expression 
of HE4 during and following progestin therapy regimens can predict a negative therapy 
response, indicating progestin resistance for medium and low risk endometrial hyperplasia 106. 
Interestingly, Orbo et al., found this in tissue samples, unlike Behrouzi et al., who found that 
HE4 was only relevant in serum samples 105.  
Key genes and pathways that mediate progesterone resistance in EC have also been 
investigated. ANO1, SOX17, CGNL1, DACH1, RUNDC3B, SH3YL1 and CRISPLD1 have all 
been indicated as being significantly enriched in a progesterone resistant cell line 6, meaning 
each of them have the potential to serve as individual predictive biomarkers.  This study simply 
observes this occurrence in one commercial cell line (Ishikawa cells), and is based off MPA 
resistant cells, rather than the Mirena® specifically. More studies utilising additional 
commercial cell lines as well as primary tissue lines should be used to investigate the 
significance of these genes and their potential role as predictive biomarkers.  
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1.5 Aim of the research 
The overall aim of this work is to investigate predictors of response to Mirena® treatment of 
early-stage EC. The aim of the current study was to identify differently expressed genes in LNG 
resistant cells compared to LNG sensitive cells, and to build a behavioural profile of LNG 
resistant cell lines. This was done by the development of LNG resistant cells from parental early 
stage endometrial cancer immortalised cell lines. The current study builds on previous work by 
Li et al (2019) 6 however, this is the first study that aims to identify predictive biomarkers using 
resistant cell lines and patient derived cell lines using RT-qPCR. It was hypothesised that the 
relative mRNA expression of key genes and the behavioural profile of LNG resistant cells, 
would differ from LNG sensitive cells. These differently expressed genes could be candidates 
for predictive biomarkers of response to Mirena® treatment.  
1.5.2 Objectives 
1. Conduct a literature search and review to identify a key set of genes that will be further 
studied as potential candidates for predictive biomarkers to Mirena® treatment.  
2. Develop LNG resistant clones from commercial cell lines and patient derived primary 
cultures. 
3. Build a behavioural profile of LNG resistant vs. LNG sensitive cells including 
proliferation, migration, adhesion and invasion to investigate their oncogenic potential.  
4. Identify promising predictive biomarkers for Mirena® treatment using RT- qPCR in the 
immortalised cell lines and patient derived cultures. 
1.6 Study Design 
A complete summary of the scientific experiments undertaken in this study are outlined in 
(Figure 5). Immortalised cell lines were split into LNG resistant and LNG sensitive cells. 
Following a period of constant treatment, behavioural assays were carried to investigate 
changes in LNG-resistant cell behaviour compared to the controls. Sixteen genes were then 
analysed in all cell lines via RT-qPCR. Primary cell lines were isolated from patient early stage 
endometrial cancers and split into LNG sensitive and LNG resistant subtypes. The top 6 




























Figure 5: Flow chart of experimental design. 
        = Develop LNG resistant clones from commercial and patient derived cell lines. 
        = Investigate the fundamental cell behavioural differences in LNG resistant vs. LNG sensitive cells  
        = Identify promising predictive biomarkers for Mirena® treatment response using RT- qPCR. 
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Chapter 2: Methods 
2.1 Literature Search 
SCOPUS, PubMed and Google Scholar were searched for the following key 
words  ("endometrial cancer*"  OR  "endometrial carcinoma*"  OR  "endometrial 
neoplasm*”)  AND  (IUD OR "intra-uterine-
device*"  OR  IUS  OR  progesterone  OR  progestin  OR  Levornogestrel  OR  "intra-uterine 
device*"  OR  "intrauterine system*"  OR  "intra-uterine system*"  OR  mirena) AND 
(“Biomarkers” OR “Marker” or “Predictive Marker*”) AND (“Response”)). Papers were 
included that were published in English, original studies or meta-analysis. More recent and 
highly citied studies were favoured.  
2.2 Ethical Approval  
Ethics approval was obtained for the use of immortalised cell lines (MFE319 and MFE296) and 
patient samples from the Wellington Hospital gynaecological cancers biobank through the 
University of Otago Health Ethics Committee. Prior ethics for the collection of patient samples 
for Biobanking purposes was granted. All patients provided written informed consent prior to 
donating to the biobank.  
2.3 Ethical considerations 
As the researcher, it was important for me to have an understanding of the informed consent 
that occurred between my supervisor, Dr Claire Henry and the patient. These patients were also 
notified that they are free to withdraw from the biobank and therefore, this research project at 
any given time.  As the researcher, it was important to de-identify patients to protect their 
confidentiality. All patient information was obtained from the REDCap database and de-
identified by the primary supervisor prior to becoming accessible to the researcher.  
2.4 Patient clinicopathological characteristics  
Age, treatment outcomes, current medications and clinicopathological information was 
obtained for each women from the REDCap database whilst maintaining patient confidentiality. 
Clinicopathological information collected included; FIGO stage, grade, histology, tumour size, 
nodal involvement, depth of myometrial invasion, dysregulated staining and lymph-vascular 
space invasion.  
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2.5 Cell Culture  
2.5.1 Immortalised Cell lines  
Endometrial cancer cell lines MFE296 and MFE319 (endometrioid endometrial cancer) were 
cultured as per the supplier's recommendations: MFE296 in Minimum Essential Medium 
(MEM) (Gibco; Thermo Fisher Scientific) containing 10% foetal bovine serum (FBS) (Gibco; 
Thermo Fisher Scientific) and MFE319 in MEM/Roswell Park Memorial Institute Medium 
(RPMI 1640) (Gibco; Thermo Fisher Scientific) containing 20% FBS. All media were 
supplemented with 100U/ml penicillin/ streptomycin (Hyclone; GE Healthcare Life Sciences). 
Cells were grown in 5% CO2 at 37 °C. Media was replaced on day one, and every three days 
subsequently. Cells were routinely passaged at 80% confluence via 1xTrypsin (Sigma-Aldrich). 
Culture media was added and the cells were centrifuged at 1000 rpm for five minutes to form 
a pellet, which was then re-suspended in fresh media. A 1:10 dilution was used to start a new 
culture flask.  
2.5.2 Primary Cell lines  
The current study used Primary cells derived from tissue samples of early-stage EC cultures 
donated by women as part of the gynaecological cancer tissue bank at Wellington hospital. One 
hour before tissue preparation, flasks were coated with 4 μg/ml type I collagen (Gibco; Thermo 
Fisher Scientific) diluted in Phosphate Buffered Saline (PBS) (Gibco; Thermo Fisher 
Scientific) to aid in the attachment and growth of human primary adenocarcinoma cells. A small 
section of endometrial cancer tissue was dissociated in the Incu-Shaker mini (Sigma-Aldrich) 
overnight using collagenase type I (Sigma-Aldrich) (10mg/mg) in TESCA buffer (50µM TES; 
0.36µM CaCl) (Sigma-Aldrich) diluted to 2mg/ml in PBS. Following dissociation, the cells 
were centrifuged at 1000rpm for five minutes to form a pellet, and resuspended in fresh culture 
media. Cells were then strained using a 40µm cell strainer to separate cancer associated stromal 
cells from adenocarcinoma cells. Both cell types were cultured separately in Dulbecco’s 
Modified Eagle Medium (DMEM/F12) (Gibco; Thermo Fisher Scientific) medium containing 
10% FBS and supplemented with 100U/ml penicillin/ streptomycin. The adenocarcinoma cells 
were used in the current study, and the separate cancer associated stromal cells were cultured 
and pelleted for future research.  Cells were grown in 5% CO2 at 37 °C. Cells were passaged 




2.6 Development of resistant cell lines  
2.6.1 LNG Treatment Determination  
After high confluence was witnessed in MFE296 and MFE319 cell line flasks (80%), cells were 
trypsinised, counted, and seeded on to a 96 well plate at a concentration of 3 × 105 cells/ml 
(MFE296 and MFE319 cell lines). Cells were incubated for 24h and then treated with escalating 
concentrations from 0-500µM of LNG (Sigma-Aldrich) dissolved in 0.001% Dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich) and incubated for a further 24h. Plates were then analysed 
using the Cell Counting Kit-8 (CCK8) (Dojindo) according to manufacturer's instructions. 
Readings at 450 nm were obtained using the Thermo Scientific TM Multiskan GO TM Microplate 
Spectrophotometer (Thermo Fisher Scientific). An increase in absorbance indicated an increase 
in cell density. LNG treatment was identified as the point of 30% cell viability for each cell 
line. Biological and technical triplicates were carried out on each cell line. 
2.6.2 Development of Resistant Cell Lines  
LNG-resistant MFE319, MFE296 and primary cell lines were obtained from parental cells via 
continuous exposure to LNG dissolved in 0.001% DMSO. MFE296 cells were treated with 
450µM LNG, MFE319 with 350µM LNG (2.6.1) and primary cells (GB #13, #16, #23) with 
100µM-200µM LNG. A DMSO control was created for each cell line at a dose of 0.001% 
dissolved in respective culture media.  
2.6.3 Determination of resistance  
Following a LNG treatment period of three months, cells were trypsinised, counted, and seeded 
on to a 96 well plate at a concentration of 3 × 105 cells/ml for the LNG sensitive cells and 6 × 105 
for the LNG resistant cells in both MFE296 and MFE319 cell lines. Cells were incubated for 
24h and then treated with escalating LNG concentrations from 0-2000µM and incubated for a 
further 24h. Plates were then analysed using CCK8 according to manufacturer's instructions. 
Comparisons were made between cell viability in the LNG sensitive cells and LNG resistant 
cells in both MFE296 and MFE319 cell lines. Biological and technical triplicates were carried 




2.7 Investigation of LNG-Resistant Behaviour  
2.7.1 Proliferation  
Cell proliferation was carried out according to Henry et al., 107. Cells were seeded in triplicate 
onto a 96 well plate at a concentration of 3 × 105 cells/ml (MFE296 and MFE319). Cells were 
stained with CCK8 according to manufacturer's instructions. Readings were obtained at 0, 24, 
48 and 72 hour time points. All absorbance values were normalised to the T0 time point to give 
the normalised proliferation of each cell line. Biological and technical triplicates were carried 
out on each cell line. 
2.7.2 Transwell Migration  
Cell migration was measured via the Boyden Chamber assay according to Henry et al., 107 
however in the current study transwell inserts were not pre-coated with collagen. 6.5mm 
transwells with 8.0μm pore polycarbonate membrane inserts (Sigma-Aldrich) were used 
according to manufacturer’s instructions. Cells were seeded in transwell inserts at a 
concentration of 3 x 105 cells/mL for MFE296 and 1 × 106 cells/ml for MFE-319. Following a 
48 hour incubation, cells were fixed with 100% ethanol and stained with 1% crystal violet. The 
membrane was then removed and mounted on a glass slide using Eukitt® Quick-hardening 
mounting medium (Sigma-Aldrich). Images were taken of four areas of the membrane using 
20x magnification. The four images were then analysed and counted using ImageJ (Java 
Software). An average cell count of the four images was then used in statistical analysis. 
Biological and technical triplicates were carried out on each cell line. 
2.7.3 Wound Migration Assay 
Cell migration was measured via a wound healing assay. Cells were plated onto a 6 well plate 
at a concentration of 1 x 106 cells/mL for MFE296 and MFE319 LNG sensitive and LNG 
resistant cell lines. Following a 24 hour incubation period, a 10uL pipette tip was used to create 
a scratch through the centre of each well. Photographs of the plates were taken at 0, 24, 48, 72 
and 96 hour time points using the 10x objective lens. Wound healing and percentage of open 
area was then measured using TScratch (CSElab software). Biological and technical triplicates 
were carried out on each cell line.  
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2.7.4 Invasion (3D Tumour Spheroid) 
Cell invasion was measured using a three-dimensional (3D) tumour spheroid invasion assay 
and carried out according to Vinci et al., 108. Hanging drop cultures were prepared on a 6 well 
plate using a cell concentration of 3x105 cells/ml (500-1,000 cells per 20 µl drop of cell culture 
media) for both MFE296 and MFE319 LNG sensitive and LNG resistant lines and incubated 
for 96 hours. Following incubation, once spheroids were visible they were embedded into a 
type I collagen/matrigel (Corning Life Sciences) matrix.  Photos were taken to monitor invasion 
at 0, 24, 48, 72 and 96 hours following plating using the 20x objective lens. Spheroid growth 
and invasion was then measured as total area of spheroids (mm2) using ImageJ (Java Software). 
Biological and technical triplicates were carried out on each cell line.  
2.7.5 2D Adhesion Assay 
Cell adhesion carried out according to Henry et al., 109. Adhesion was only measured against 
collagen type I (rat tail) (Gibco; Thermo Fisher Scientific). Tissue culture plates were coated 
with collagen (10µg/ml) and 3 % bovine serum albumin (BSA) PBS. Coated plates were 
incubated for 24 h at 37 °C and then rinsed with 80 % ethanol.  3 % BSA in PBS was added to 
each well and incubated for a further 30 min at 37 °C. After rinsing with PBS, concentrations 
of 5 x 105 cells/mL for all cell lines in serum free media were added to the coated plates and 
left to adhere at 37 °C for 1 h. Following incubation, plates were washed 3 times with PBS and 
fixed with 100 % ethanol before being stained with 0.1 % crystal violet at room temperature 
for 30 min. Plates where then washed extensively with water to remove excess staining and 
then left to dry. Once dried, cells were lysed with 50 % acetic acid. Absorbance was measured 
at 595nm using the Thermo Scientific TM Multiskan GO TM Microplate Spectrophotometer. 
Biological and technical triplicates were carried out on each cell line. 
2.8 Analysis of mRNA expression using qPCR 
2.8.1 Primer Design 
NCBI Primer Blast was used to create a list of potential primers for each of the genes (Table 
3). Primers were chosen if the product length was between 70-250bp and had a melting point 
(Tm) close to 60°C with the Tm of the forward and reverse primers as similar as possible. 
Primers that contained a C or G residue at the 4. 3′ end of the primer were preferred over ones 
that did not, as T and A residues bind more easily to DNA in a non-specific way. A GC content 
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of around 40-60% was considered optimal to ensure maximum product stability. And primers 
with low self-complementarity were selected to decrease the possibility of primer-dimer 
formation. Primers were also investigated for non-specific target binding. Primers with the 
fewest non-specific targets were selected.  
2.8.2 RNA extraction 
RNA extraction was carried out according to Henry et al.,110. LNG resistant cells and LNG 
sensitive controls for MFE319, MFE296, GB#13, GB#16 and GB#23 cells were harvested, 
pelleted, and the RNA from these cells extracted using the zymo RNAeasy kit (In Vitro 
Technologies) according to the manufacturer’s instructions. RNA quantification (in ng/µL) and 
purity was assessed using the NanoDrop spectrophotometer (Thermo Fisher Scientific). A 








Figure 6: Example of an optimal RNA extraction 
Example of an optimal RNA extraction result. 260/280 and 260/230 are both ~2.  
 
2.8.3 cDNA synthesis 
Conversion of RNA (1μg) to double stranded cDNA was carried out using the QuantiTect® RT 







2.8.4 RT-qPCR  
qPCR analysis was carried out according to Henry et al., 110. 25 ng of cDNA, 100 nM of primers 
and 12.5μL SYBRGreen master mix (Qiagen) was used in each reaction. RT-qPCR cycling 
conditions were 95°C for 10mins, (95°C for 15 seconds, 60°C for 30 seconds, 72°C for 40 
seconds) for a total of 40 cycles and then 95°C for 60 seconds, followed by melt curve 
analysis. mRNA was measured using Threshold cycle (Ct) values and the threshold was 
automated during the log phase of replication for each run (Figure 7). The cut off Ct value was 
40.  Strong reactions were Ct values (≤ 29), positive reactions were Ct values (30-35), and Ct 
values >35 were considered weak expression. Biological and technical triplicates were carried 
out, and triplicate Ct values were averaged. 
111. Ct values were analysed using the Vandesompele 
normalisation method 112 against three housekeeping genes Succinate Dehydrogenase Complex 
Subunit (SDHA), 90 kDA Heat Shock Protein 1 Beta (HSPCB) and 60S Ribosomal 
ProteinL13a (RPL13A).  Results are expressed as comparative threshold (ΔCt). Melt curve 
analysis was carried out following RT-qPCR procedure to determine the specificity of primers 
(Figure 8). No reverse transcriptase controls were used as a negative control to identify any 







Figure 7: Example of RT-qPCR amplification curve (RPL13A) 









Figure 8: Example of an optimal RT-qPCR melt curve (RPL13A) 
Representation of single binding with the RPL13A primers. Only one peak should be observed to indicate specific 





Table 3: Primers used for RT-qPCR Procedure 
GENE PRIMER PRODUCT 
LENGTH 
GC% Tm 
CACNA2D3 F: TGATGTGGTGTGGACCGAAG 
R: GCCCTTCGATCTGGTTTCGT 




HOTAIR F: CCAGCCCTAGCCTTTGGAAG 
R: GCTGCCAGTTAGAAAAGCGG 




SATB2 F: GGAGAACGACAGCGAGGAA 
R: CCGATGTATTGCTTTGCCTAGT 




HE4 F: GTTCGGCTTCACCCTAGTCTC 
R: CAGGAACCCTCCTTATCATTGGG 




DKK1 F: ACAACTACCAGCCGTACCC 
R: TGCAGGCGAGACAGATTTGC 




KLF4 F: ACCCCACCTTCTTCACCC 
R: TAAGGTTTCTCACCTGTGTGG 




ANO1 F: GAGCCAAAGACATCGGAATCTG 
R: TGAAGGAGATCACACGAAGGCAT 




SOX17 F: AGTGACGACCAGAGCCAGAC 
R: CCTTAGCCCACACCATGAAA 




CGNL1 F: GGCTGAGGAGGAAATCGACA 
R: ACTCGGCAGCTTCTTCAGTCTTA 




DACH1 F: TGCCGCATTCTGTCCCT 
R: GAGTCTGCTCCATGTTGGTTATT 




RUNDC3B F: TGGATGGCAGTTTTCCTGCT 
R: ACCACTGCTTCCCAAAGTCC 




SH3YL1 F: CCGCAGGTACGCCCTC 
R: AGGTATAGGGTTATTCATGCTGCCC 






GENE PRIMER PRODUCT 
LENGTH 
GC% Tm 
CRISPLD1 F: GATATAGGCCCCCGACGTTT 
R: CCCACCAGTTTCCCCTGTGT 




PRB F: GGTCTACCCGCCCTATCTCA 
R: TAGTTGTGCTGCCCTTCCAT 
195 F: 60.00 
R: 50.00  
F: 60.18 
R: 59.30 
 ER F: TGGGAATGATGAAAGGTGGGAT 
R: GGTTGGCAGCTCTCATGTCT 




FOXO1  F: CTGAGGGTTAGTGAGCAGGTTAC 
R: CTGCCAAGTCTGACGAAAGG 




RPL13A F: CCTGGAGGAGAAGAGGAAAGAGA 
R: TTGAGGACCTCTGTGTATTTGTCAA 




SDHA F: TGGGAACAAGAGGGCATCTG 
R: CCACCACTGCATCAAATTCATG 




HSPCB F: TCTGGGTATCGGAAAGCAAGCC 
R: GTGCACTTCCTCAGGCATCTTG 




2.9 Statistical Analysis  
Raw data was organised and stored in Excel 2016 (Microsoft Corporation). Data was then added 
into Prism v8.0 (GraphPad) for development of graphs and statistical analysis. Unpaired testing 
was used in the current study as LNG resistant cells and LNG sensitive cells are treated as two 
independent cell lines. An unpaired Student’s t Test was carried out for determination of 
resistance, transwell migration and adhesion assays to compare values between LNG resistant 
and LNG sensitive cell lines. All values are represented as mean ± SEM unless otherwise stated. 
An f test was used to determine variances in standard deviation prior to t Test analysis. An 
unpaired Student’s t Test was carried out on the mean of each time point for wound healing 
migration and proliferation to give significance at each time point. Technical and biological 
triplicates (n=3) were carried out for each experiment. An unpaired student’s t Test was carried 
out for comparison of differently expressed genes between LNG resistant and LNG sensitive 
MFE296, MFE319, GB#13, GB#16 and GB#23 cell lines. A p value of ≤ 0.05 was considered 
statistically significant. Chapter 3: Results  
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Chapter 3: Results 
3.1 Literature search  
Articles were critically assessed and genes were selected due to their implication in 
progesterone resistance in endometrial cancer (EC) and hyperplasia treatment. A table outlining 
these papers, and the implicated genes can be seen in Table 1. From this, 12 genes were chosen 
based on the study outcome and significance. A further four genes were selected due to their 
relationship to EC.   
 
Table 4: List of Genes implicated as predictive biomarkers to progesterone treatment from the 
literature 
Gene Full name Why it was chosen EC/Hyperplasia Study/studies 
HOTAIR HOX antisense 
intergenic RNA 
Knockdown predicts 
negative response to 
progesterone therapy  
EC Chi et al., 
(2019)113 
HE4 Human epididymis 
protein 4 
Low expression predicts 
a positive response to 
progesterone therapy 
(including Mirena®) 
Early stage (1a) EC 
and hyperplasia 
Behrouzi et al,. 
(2020)82, Orbo et 
al., (2016)106  
ANO1 Anoctamin 1 Upregulated in 
progesterone resistant 
ishikawa EC cells 






ishikawa EC cells 
EC Li et al., (2019)6 
CGNL1 Cingulin Like 1 Upregulated in 
progesterone resistant 
ishikawa EC cells 
EC Li et al., (2019)6 





ishikawa EC cells 







ishikawa EC cells 
EC Li et al., (2019)6 
SH3YL1 SH3 And SYLF 
Domain Containing 1 
Upregulated in 
progesterone resistant 
ishikawa EC cells 
EC Li et al., (2019)6 






ishikawa EC cells 
EC Li et al., (2019)6 
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FOXO1 Forkhead Box Low expression predicts 
a negative response to 
Mirena® 




Low expression predicts 
a negative response to 
progesterone therapy 
(including Mirena®) 
 Reyes et al., 
(2016)114, Upson 
et al., (2012) 96, 
Akesson 
(2012)100, Gallos 
et al., (2013)97 
ER Estrogen Receptor High expression predicts 






Dickkopf WNT signalling pathway inhibitor 1 (DKK1), Kruppel-like factor 4 (KLF4) SATB 
homeobox 2 (SATB2) and Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3 
(CACNA2D3) have not been previously investigated as potential predictive biomarkers. DKK1 
was included in this study as EC patients show increased DKK1 expression, and expression 
correlated to the stage of cancer 115. DKK1 is also a Wnt Inhibitor that is induced by 
progesterone 116 and has shown to inhibit migration and invasion in Ishikawa EC cells 117. KLF4 
was chosen as it acts as a stem cell factor promoting Epithelial to Mesenchymal Transition 
(EMT) in EC, and would therefore be interesting to relate back to the behavioural profiles of 
the LNG resistant cells. SATB2 was chosen for this study due to its prognostic value in 
endometrioid ovarian cancer 118. CACNA2D3 was chosen as progesterone inhibits apoptosis 













3.2 Patient Cohort  
Table 5: Demographic and clinicopathological characteristics for patient cohort: Three primary cultures 
samples were developed from three separate patients for pilot LNG resistance analysis. Table 5 outlines patient 
clinicopathological characteristics and histological/FIGO diagnosis.  BSO: Bilateral Salpingo-Oophorectomy, LVSI: 
Lymph Vascular Space Invasion.  
 
GB #13 GB #16 GB #23 
Age at diagnosis 73 73 62 
BMI 46 28 39 
Parity 1 2 3 
Treatment 
method 
Hysterectomy + BSO Hysterectomy + BSO + 
Bilateral node dissection  
Hysterectomy + BSO 
Diagnosis before 
surgery 




following surgery  
Stage: IIIB  
Grade: 2  
Stage: IB  
Grade: 3 




Clear cell  Endometrioid 
LVSI Yes No No 
Tumour Size 39 x 25 x 17 mm 36 x 33 x 20 mm 50 x 30 x 16 mm 
Nodal 
involvement 
No No Staging incomplete – nodes 
not removed due to 
technical challenges of 




23.5mm of 25mm 10mm of 17mm 2mm of 10mm  
Molecular 
subtyping 
Loss of MLH1/PMS2 P53/P16 overexpression, 
wt1 (-), napsin A (-), ER (-), 
HBM E-1 (-) vimentin (+) 





200µm 200µm 200µm 
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3.3 Determination of LNG Treatment concentrations 
A high-level laboratory resistance model was used 120  to develop resistant cell lines. To 
determine the concentration of LNG the cells were constantly exposed to in order to develop 
resistance, a kill curve was carried out. CCK8 was used to observe cell viability across 
increasing LNG concentrations from 0µM to 500µM. The point at which 30% viability was 
observed was chosen as the LNG concentration for long term treatment. For MFE296, this point 
was 450uM LNG and for MFE319 cell lines this was 350µM LNG. (Figure 9). 
  






































Figure 9: Determination of LNG treatment concentrations  
Cell lines respectively after increasing LNG doses of 0µM, 50µM, 100µM, 150µM, 200µM, 250µM, 300µM, 
350µM, 400µM, 450µM, 500µM. A) In the MFE296 cell line, 30% cell viability observed at 450µM, 
represented on the graph by the orange line. B) In the MFE319 cell line, 30% cell viability observed at 350µM, 






3.4 Resistance Determination  
Once limited cell death was occurring with ongoing treatment in the LNG resistant cell line, a 
second kill curve was carried out using CCK8 to confirm resistance. From here forth, parental 
LNG sensitive cell clones (S) and LNG resistant clones (R) will be referred to as 
MFE296S/MFE319S and MFE296R/MFE319R respectively. MFES cell clones were treated with 
0.01% DMSO as the vehicle control for LNG. Cells were treated with increasing concentrations 
of LNG from 0µM to 2000µM and cell viability was monitored. Both resistant cell lines 
(MFE296R and MFE319R) have increased cell viability in comparison to the control cell lines 
(MFE296S and MFE319S) when exposed to increasing doses of LNG. Significance was 
determined using an unpaired student’s t test. (Figure 10A-B).  
MFE296 
The cell viability of MFE296R cells is higher than that in MFE296S cells. This is statistically 
significant at LNG concentrations of: (200µM: p=0.00019, 400µM: p=0.0173, 600µM: 
p=0.0011, 800µM: p=0.0088, 1000µM: p=0.0277, 1200µM: p=0.0443, 1400µM: p=0.0473) 
Treatment of the MFE296 cells with LNG concentrations of 1600µM, 1800µM and 2000µM 
did not cause any significant change in cell viability. (Figure 10A). 
MFE319 
The cell viability of MFE319R cells is higher than that in MFE319S cells. This is statistically 
significant at all LNG concentrations except 200µM (400µM: p= 0.0358, 600µM: p=0.0052, 
800µM: p=0.0048, 1000µM: p=0.0002, 1200µM: p=0.0174, 1400µM: p=0.0046, 1600µM: 































































Figure 10: Resistant cell lines have increased cell viability in comparison to the control cell lines 
when exposed to increasing doses of LNG. 
Cell viability assay results showing the difference in cell viability (observed as CCK8 absorbance levels) of A) 
MFE296S (pink) and MFE296R (blue) and B) MFE319S (pink) and MFE319R (blue) cell lines respectively after 
increasing LNG doses. Both resistant cell lines (MFE296R and MFE319R) have increased cell viability in 
comparison to the control cell lines (MFE296S and MFE319S) when exposed to increasing doses of LNG. 
Results are expressed as mean  SD, experiments performed in triplicate (n=3). Individual groups were 
analysed using T-test. α = 0.05 is used as the minimum requirement to recognise statistical significance. 






3.5 LNG resistance has some effect on cellular proliferation  
There was no significant difference in cell proliferation between LNG resistant cells and LNG 
sensitive control cells apart from a significant decrease in MFE319R absorbance and therefore, 
cell density at the 48 hour time point (MFE319S: 1.535 ± 0.12, MFE319R: 1.23 ± 0.07) (P<0.05). 
Proliferation increased at a similar rate in both cell lines over a period of 72 hours. This 
observation was conserved in both LNG treated cells and controls. (Figure 11A-B). 







Figure 11: LNG treated cells proliferate at the same rate as controls in immortalised cell lines  
Cell survival assay results showing the difference in cell proliferation (observed as CCK8 absorbance levels) 
of A) MFE296R (blue) and MFE296S (pink) and B) MFE319R (blue) and MFE319S (pink) cell lines respectively. 
Proliferation rate is displayed as relative to LNG sensitive controls. A) Proliferation rate does not differ 
between the treated and control cells in the MFE296 cell line. B) Proliferation rate significantly decreased in 
the MFE319R cells at the 48h time point. Results are expressed as mean  SD, results are done in triplicate 
(n=3). Individual groups were analysed using T-test. α = 0.05 is used as the minimum requirement to 

























































3.6 The effect of LNG resistance on cell migration  
3.6.1 LNG resistance increases transwell migration in the MFE319 cell line  
Transwell migration was measured after cells were incubated on corning inserts for 48 hours. 
Cell migration is represented by the number of cells present on the membrane following 
staining were counted using Image J. Significance was determined using an unpaired student’s 
t test. 
MFE296 
There was no significant difference in Boyden chamber transwell migration between MFE296R 
cells and MFE296S cells (n=3). (Figure 12A). Representative images of MFE296 transwell 











Figure 12: LNG resistance has no effect on transwell migration in the MFE296 cell line 
Transwell migration assay results showing the difference in MFE296 cell migration. A) MFE296R (blue) and 
MFE296S (pink). Migration is displayed as number of migrated cells on a transwell membrane (average of 
four quadrant counts). Migration rate does not differ between the MFE296R and MFE296S cells. Results are 
expressed as mean  SD, experiments performed in triplicate (n=3). Individual groups were analysed using 
T-test. α = 0.05 is used as the minimum requirement to recognise statistical significance. Significance is 















































A significant increase in Boyden chamber transwell migration was observed in the MFE319R 
cells compared MFE319S cells (MFE319S: 210.31 ± 9.24, MFE296R: 254.62 ± 31.77) (P =0.03) 
(n=3). (Figure 13A). Representative images of MFE319 transwell migration can be observed 






























































Figure 13: LNG resistance increases transwell migration in the MFE319 cell line 
Transwell migration assay results showing the difference in cell migration. A) MFE319R (blue) and MFE319S 
(pink) cell lines respectively. Migration is displayed as number of migrated cells on a transwell membrane 
(average of four quadrant counts). Results are expressed as mean  SD, experiments performed in triplicate 
(n=3). Migration significantly increased in the MFE319R cells compared to MFE319S cells. Individual groups 
were analysed using T-test. α = 0.05 is used as the minimum requirement to recognise statistical significance. 







3.6.2 LNG resistance has some effect on wound migration in immortalised cell 
lines  
Wound healing migration was quantified as percentage of open area measured using Image J. 
Closure of this open area was monitored over a period of 96 hours following the scratching of 
a confluent well. Significance was determined using an unpaired student’s t test. 
 
MFE296 
A significant increase in migration was observed in the MFE296R cell line at the 72 hour time 
point compared to the MFE296S control (MFE296S: 11.33 ± 0.57, MFE296R: 8.66 ± 1.15) (p= 
0.0232) represented by a smaller % open area. There was no significant difference in migration 
at any other time points. Overall, the MFE296R cells appear to migrate faster than the MFE296S 
cells, however this observation was not significant (Figure 14A). Representative images of 













Figure 14A-B: LNG resistance has some effect on wound migration in MFE296 immortalised cells. 
A) Wound migration assay results showing the difference between MFE296S and MFE296R wound migration. 
Migration significantly increased in the MFE296R cells at the 72h time point compared to MFE296S cells. 
Wound migration is displayed as % open area. Results are expressed as mean  SD, results are done in 
triplicate (n=3). Individual groups were analysed using T-test. α = 0.05 is used as the minimum requirement 
to recognise statistical significance. Significance is shown via (*).  * P <0.05. B) Representative would healing 





































There was a significant decrease in wound migration in the MFE319R cell line at the 24 hour 
time point compared to the MFE319S control (MFE319S: 8.66 ± 0.57, MFE319R: 14 ± 2.31)  
(p=0.0436) represented by a larger % open area. There was no significant difference in 
migration at any other time points (Figure 15B). Overall, the MFE319R cells appear to migrate 
slower than the MFE319S cells, however this observation was not significant. (Figure 15A). 
Representative images of wound healing is shown in (Figure 15B). Significance was 









3.7 LNG decreases cell invasion in MFE296 cells and increases cell 
invasion in MFE319 cells  
Invasion rate was measured via a 3D spheroid invasion assay embedded in an ECM matrix of 
collagen type I and matrigel. Spheroid size (mm2) was monitored every 24h for a total of 96h 
and then measured using Image J. 
Figure 15A-B: LNG resistance has some effect on wound migration in MFE319 immortalised cells. 
A)  Wound migration assay results showing the difference between MFE319S and MFE319R wound migration. 
MFE319R and MFE319S cell lines Wound migration significantly decreased in MFE319R cells at the 24h time 
point. Wound migration is displayed as % open area. Results are expressed as mean  SD, results are done 
in triplicate (n=3). Individual groups were analysed using T-test. α = 0.05 is used as the minimum 
requirement to recognise statistical significance. Significance is shown via (*).  * P <0.05. B) Representative 
would healing in MFE319S and MFE319R cells. Images taken using 4x objective. Yellow lines represent the % 





































Invasion was attenuated in MFE296R cells compared to MFE296S cells (n=1, triplicate 
spheroids). Both MFE296 cell types showed an increase in rate from the 72h-96h time point 
compared to 0h-72h. (Figure 16A). The average size of the spheroids at T0 was smaller in the 
MFE296R cells (0.013mm2 ± 0.007mm2) compared to the MFE296S cells (0.025mm2 ± 
0.01mm2). (Figure 16A-B). Representative images of MFE296 spheroids can be seen in 











Invasion was increased in the MFE319R cells compared to the MFE319S cells (n=1, triplicate 
spheroids) (Figure 17A). The average size of the spheroids at T0 was smaller in the MFE296S 
cells (0.0023mm2 ± 0.0005mm2) compared to the MFE296R cells (0.005mm2 ± 0.001mm2). 
(Figure 17A-B). Representative images of MFE319 spheroids can be seen in (Figure 17B). 





Figure 16: Cells from MFE296R spheroids are less invasive than MFE296S tumour spheroids when 
placed in a collagen/matrigel matrix. 
A) Individual spheroid results of 3 technical replicates in the MFE296 cell line. MFE296S spheroids are larger 
at T0 than MFE296R spheroids at each time point. Cells from MFE296R spheroids are invading into the 
collagen/Matrigel less than cells from MFE296S spheroids. B) Representative images of MFE296S and MFE296R 
spheroids. (n=1, triplicate spheroids). Images taken using 20x objective. Yellow lines represent the area of the 
spheroid (mm2) 












































3.8 LNG resistance decreases cellular adhesion   
Cellular adhesion was evaluated through the ability of respective cell lines to adhere to collagen 
in 1 hour. Adhesion is measured following crystal violet staining via absorbance of each cell 
line at 595nm. Significance was determined using an unpaired student’s t test. 
Adhesion was significantly attenuated in the MFE296R cells (absorbance: 0.662 ± 0.11) 
compared to the MFE296S cells (absorbance: 0.308 ± 0.088) after one hour (p=0.012). (Figure 
18A). Adhesion was also attenuated in the MFE319R cells (absorbance: 0.822 ± 0.18) compared 
to the MFE319S cells (absorbance: 0.502 ± 0.06) after one hour (p=0.04). (Figure 18B). 
Overall, the MFE319 cell line was more adherent than the MFE296 cell line. BSA served as a 
negative control for cell adhesion.  
 
 
Figure 17: Cells from MFE319R spheroids are more invasive than MFE319S tumour spheroids when 
placed in a collagen/matrigel matrix.  
A) Individual spheroid results of 3 technical replicates. Cells from MFE319R spheroids appear to be larger at 
each time point that cells from MFE319S spheroids. MFE319S spheroids are smaller at T0 than MFE319R 
spheroids. Cells from MFE319R spheroids are invading into the collagen/Matrigel matrix more than cells from 
MFE319S spheroids. B) Representative images of MFE319S and MFE319R spheroids. (n=1, triplicate 



















































Figure 18: LNG resistance decreases adhesion in immortalised cell lines 
Adhesion assay results showing the difference in cell adhesion. A) MFE296R and MFE296S and B) MFE319R 
and MFE319S cell lines respectively. A) Adhesion is significantly decreased in the MFE296R cells compared 
to MFE296S cells. B) Adhesion is significantly decreased in MFE319R cells compared to MFE319S cells.  
Adhesion is displayed as Absorbance of crystal violet at 595nm. BSA served as a negative control. Results 
are expressed as mean  SD, experiments performed in triplicate (n=3). Individual groups were analysed 
using T-test. α = 0.05 is used as the minimum requirement to recognise statistical significance. Significance 






















































3.9 LNG resistant cells express different levels of mRNA to LNG 
sensitive cells in immortalised cell lines.   
RT-qPCR was preformed to identify differentially expressed genes (DEG’s) between LNG 
resistant and LNG sensitive MFE296 and MFE319 cell lines.  Custom primers were created for 
the 16 genes identified in 3.1, using NCBI Primer Blast. mRNA expression was measured using 
RT-qPCR. Expression is displayed as relative to sensitive cell controls. Using α = 0.05 as cut-
off criteria for statistical significance, 10 DEGs were identified in the MFE296 cell line and 
eight DEGs were identified in the MFE319 cell line. mRNA expression of HOTAIR was not 
detectable in all samples. Significance was determined using an unpaired student’s t test. 
MFE296 
Expression of CRISPLD1, CGNL1, DACH1, ER, KLF4, DKK1, SATB2, SOX17, ANO1 and 
HE4 were all significantly upregulated the MFE296R cells in comparison to MFE296s cells. 
(Figure 19A). (CRISPLD1: (p=0.00185), CGNL1: (p=0.0013), DACH1: (p=0.00111), ER: 
(p=0.0116), KLF4: (p=0.00244), DKK1: (0.0311), SATB2: (p=0.000129), SOX17: 
(p=0.000121), ANO1: (p=0.01246), HE4: (p=0.0203)). Expression of CRISPLD1 and SOX17 
was not detectable in the MFE296s cells.    
MFE319 
Expression of CRISPLD1, RUNDC3B, KLF4, SATB2, SOX17, CACNA2D3, ANO1 and HE4 
were all significantly upregulated the MFE319R cell lines in comparison to MFE319s cells, 
while DKK1 expression was significantly downregulated in the MFE319R cells. (Figure 19B). 
(CRISPLD1: (p=0.0388), RUNDC3B: (p=0.0142), KLF4: (p=0.00737), SATB2: (p=0.00645), 
SOX17: (p=0.0347), CACNA2D3: (p=0.00217), ANO1: (p=0.04239), HE4: (p=0.00982), 







Figure 19A-B: LNG treated cells express different levels of mRNA to controls. 
RT-qPCR was performed in triplicate and Ct values were normalised to three different housekeeping genes 
(SDHA, HSPCB, and RPL13A) A) ΔCt mRNA expression of key genes in the MFE296S and MFE296R cell lines. 
B) ΔCt mRNA expression of key genes in the MFE319S and MFE319R cell lines.  Results are expressed as mean 
 SD, experiments were performed in triplicate (n=3). Individual groups were analysed using T-test. α = 0.05 
is used as the minimum requirement to recognise statistical significance. Significance is shown via (*). * P 


























































































































































































Using the Versatile matrix visualization and analysis software (Morpheus) from The Broad 
Institute 121 A clustering heatmap of the 15 altered DEGs in immortalised cell lines (Figure 
20). Across both cell lines, mRNA expression of CRISPLD1, KLF4, SATB2, SOX17, ANO1 






Figure 20: Heat map of 15 altered DEGs in immortalised cell lines  
Heat map depicting the 15 DEGs across the resistant and control cell lines.  Red indicates a ΔCt mRNA expression 
of >2. Blue indicates an expression of <1. KLF4, SOX17, SATB2, ANO1 and HE4 were significantly amplified in 
MFE296R and MFE319R cell lines in comparison to MFE296S and MFE319S cell lines. Expression of CRISPLD1 and 






















Figure 21A-F: Top 6 DEGs in immortalised cell lines  
RT-qPCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, 
and RPL13A). Expression is displayed as relative to LNG sensitive controls. A) CRISPLD1, B) SATB2, C) KLF4, 
D) ANO1, E) SOX17 and F) HE4 were all significantly upregulated in LNG resistant cells (blue) compared to 
LNG sensitive cells (pink) in both MFE296 and MFE319 cell lines. The mean of each biological replicate is 
displayed on the graph as squares (LNG resistant cells) or circles (LNG sensitive cells).  Results are expressed 
as mean  SD, experiments were performed in triplicate. Individual groups were analysed using T-test. α = 
0.05 is used as the minimum requirement to recognise statistical significance. Significance is shown via (*). 










3.9.1 Ct Values  
All Ct values across the significant DEG’s were identified as either strong reactions (≤ 29), or 
positive reactions (30-35), >35 is considered weak expression. KLF4 across all cell lines and 
HE4 in the MFE319 cell line were associated with the lowest overall Ct values. SOX17 was 
associated with weak Ct values. (Table 6). All Ct values can be seen in (Appendix 1, Table 
S1-S2).  Representative melt curves for all significant DEGs can be seen in (Appendix 1, 
Figure S1).  
Table 6: DEG’s and their associated Ct values for RT-qPCR analysis.  
Gene Cell line Positive Reaction: Ct 
(30-35) 
Strong Positive 
Reaction: Ct (≤29) 
HE4 MFE319S  
MFE319R 
 22.75 ± 0.40 (S) 





32.31 ± 0.90(S) 
30.01 ± 1.44(R)  
30.83 ± 2.09(S) 
30.70 ± 0.85(R) 
 




34.43 ± 2.6(S) 
 
34.43 ± 0 (S)  
35.80 ± 0.1 (R) 
 
29.64 ± 5.9(R) 




30.92 ± 0.51(S) 
 
 
24.60 ± 0.55 (R) 
23.78 ±0.27(S) 





31.58 ± 1.35 
  
 
27.78 ± 0.32 
28.31 ± 0.19  





3.9.2 LNG resistant cells express different levels of mRNA to controls in primary 
cell lines 
Using the 6 DEGs identified in immortalised MFE296 and MFE319 cell lines alongside 
hormone receptors ER and PR, RT-qPCR was carried out on primary cell samples from women 
diagnosed with early stage endometrial cancer.   
GB#13   
Results show upregulation in the relative mRNA expression of SOX17  (GB#13S: 0.746 ± 0.89, 
GB#13R: 13.19 ± 0.005) ANO1 (GB#13S: 0.00, GB#13R: 17.89 ± 0.09), SATB2 (GB#13S: 0.00, 
GB#13R: 15.91 ± 0.24), KLF4 (GB#13S: 0.00, GB#13R: 17.57 ± 0.09) and ER  (GB#13S: 0.00, 
GB#13R: 18.94 ± 0.04)  in the GB#13R cells compared to the GB#13S cells. Expression of 
ANO1, ANO1, SATB2, KLF4, ER and CRISPLD1 was not detectible after 40 qPCR cycles in 
GB#13S cells. CRISPLD1 was also non-detectable in the GB#13R primary line. (Figure 22).  
GB#16  
Results show upregulation in the relative mRNA expression of ANO1 (GB#16S: 0.00, GB#16R: 
0.229), SATB2 (GB#16S: 0.281, GB#16R: 1.077), KLF4 (GB#16S: 0.226, GB#16R: 1.03), 
CRISPLD1 (GB#16S: 0, GB#16R: 1.050) and HE4 (GB#16S: 0.019, GB#16R: 0.989) in the 
GB#16R cells compared to the GB#16S cells. A downregulation in the relative mRNA 
expression of PR (GB#16S: 1.02, GB#16R: 0.70), SOX17 (GB#16S: 3.026, GB#16R: 0.006) and 
ER (GB#16S: 3.05, GB#16R: 0.002) in GB#16R cells compared to GB#16S cells is observed, 
different to what has been conserved across immortalised cell lines and GB#13 cells. 
Expression of CRISPLD1 was not detectible in the GB#16S cells after 40 qPCR cycles. (Figure 
23).  
GB#23   
Results show upregulation in the relative mRNA expression of SOX17 (GB#23S: 0.297, 
GB#23R: 0.835), KLF4 (GB#23S: 0.270, GB#23R: 0.984), ER (GB#23S: 0.092, GB#23R: 
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0.961), CRISPLD1 (GB#23S: 0.0001, GB#23R: 1.07), and HE4 (GB#23S: 0.469, GB#23R: 
0.951) in the GB#23R cells compared to the GB#23S cells. A downregulation in the relative 
mRNA expression of ANO1 (GB#23S: 0.960, GB#23R: 0), SATB2 (GB#23S: 1.00, GB#23R: 
0.162),  and PR (GB#23S: 0.934, GB#23R: 0), in GB#16R cells compared to GB#16S cells is 
observed, different to what has been conserved across immortalised cell lines and GB#13 cells. 
Expression of PR and ANO1 were not detectible after 40 qPCR cycles in the GB#23R cell line. 













Figure 22: LNG treated cells express different levels of mRNA to controls in GB#13 primary 
cells  
RT-qPCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, 
HSPCB and RPL13A). Expression is displayed as relative to LNG sensitive controls. KLF4, SOX17, SATB2 and 
ER were significantly amplified in GB#13R cell lines in comparison to GB#13S cell lines. Expression of ER, 
KLF4, SATB2 and SOX17 were not detectable in the GB#13s cells. Expression of CRISPL1 and PR was not 


































































Figure 23: LNG treated cells express different levels of mRNA to controls in GB#16 primary cells  
RT-qPCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB, 
and RPL13A). Expression is displayed as relative to LNG sensitive controls. ANO1, SATB2, KLF4, CRISPLD1 and 
HE4 were significantly amplified in GB#16R cell lines in comparison to GB#16S cell lines. Expression of SOX17, 
PR and ER were all significantly downregulated in GB#16R cell lines in comparison to GB#16S cell lines. 




Figure 24: LNG treated cells express different levels of mRNA to controls in GB#23 primary cells  
RT-qPCR was performed in triplicate and normalised to three different housekeeping genes (SDHA, HSPCB 
and RPL13A). Expression is displayed as relative to LNG sensitive controls. KLF4, SOX17, CRISPLD1, HE4 and 
ER were significantly amplified in GB#23R cell lines in comparison to GB#23S cell lines. Expression of CRISPLD1 
was not detectable in the GB#23s cells and PR expression was not detectable in GB#23R cells. Expression of 




































































































Chapter 4: Discussion  
4.1 Key findings  
The overall aim of this work is to investigate predictors of response to Mirena® treatment of 
early-stage EC. The aim of the current study was to identify differently expressed genes in LNG 
resistant cells compared to LNG sensitive cells, and to build a behavioural profile of LNG 
resistant cell lines. The current study showed that LNG resistance had no effect on proliferation 
however significantly increased transwell migration in MFE319R cells, decreased invasion in 
MFE296R cells, increased cell invasion in MFE319R cells , and decreased cellular adhesion to 
collagen in MFE29R cells and MFE319R cells. Proliferation and wound migration were slightly 
affected by LNG resistance. Transwell migration in MFE296R cells was unaffected by LNG 
resistance. This is an indication that the LNG resistant cells may behave more aggressively than 
the LNG sensitive cells and have stronger oncogenic potential. This is important information 
to take into further studies as it may change the treatment pathway of women whose tumours 
are identified as resistant to the Mirena®. Sixteen potential biomarkers were identified in the 
literature and mRNA expression was investigated in LNGR and LNGS cell lines. Expression of 
CRISPLD1, KLF4, SATB2, SOX17, ANO1 and HE4 were significantly upregulated in 
resistant cell lines (MFE296R and MFE319R) compared to LNGS controls. This study suggests 
that these genes may serve as predictive biomarkers for response to the Mirena®. This chapter 
will discuss the key findings in depth and their relevance in the field of EC. The limitations, 
future directions and clinical relevance of the current study will also be discussed.  
4.2 Selection of immortalised cell lines   
The MFE319 and MFE296 cell lines were chosen for the current study due to their stability and 
ease of maintenance. The more common endometrial cancer cell lines such as Ishikawa, HEC-
1-A, HEC-1-B- and KLE were not chosen in this study due to confliction regarding their 
phenotype (type I or type II). Some studies have reported these cell lines as type I, while others 
have referred to them as type II 122. Due to the nature of this study, it was vital that the 
immortalised cell lines chosen were type I. MFE319 and MFE296 cells have been reported as 
having relatively higher levels of hormone receptor (PR, PR-B and ER) levels, making them a 
suitable model for studying hormonal responses in cell culture 123. MFE296 was previously 
shown to be inhibited by progesterone treatment, therefore this line was a good candidate model 
for identifying the development of progesterone resistance. Both MFE296 and MFE319 have 
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low mismatch repair methylation and high levels of PTEN mutations (a gene commonly 
mutated in the progression of endometrial hyperplasia to type I EC)123.  
4.3 Patient cohort  
The patients selected for this opportunistic, pilot cohort were women undergoing surgery for 
the treatment of early-stage endometrial cancer at the Wellington Regional Hospital. The 
inclusion criteria was a pre-operative diagnosis of FIGO stage I. The samples were collected as 
a part of the gynaecological cancer tissue bank at Wellington hospital. The total number of 
women recruited in the cohort was three. Originally, it was planned to have a larger sample 
size, yielding more power and generalizable data, however, due to factors beyond the 
researchers control such the shortened time frame and the cancellations of elective surgeries 
during COVID-19 lockdown, the sample size achievable was smaller. This preliminary analysis 
was conducted to begin the optimisation process of primary cell culture. The next step of this 
study would be to work with larger patient cohorts to validate findings from the current study.  
Patient GB#13 had a clinical diagnosis of endometrioid adenocarcinoma grade 1 following a 
pipelle biopsy. Following surgery and histopathological evaluation, the cancer was re-
diagnosed as endometrioid adenocarcinoma grade 2 stage IIIB. This cancer was not ideal in the 
context of the current study however, the sample was still processed, treated with LNG and 
results were collected for the purpose of optimisation of primary tissue culture. Interestingly, 
patient GB#13 had an abnormal loss of staining in MHL1/PMS2 DNA mismatch repair (MMR) 
genes. MHL1 is downregulated in ~40% of endometrial cancer cases due to its integral 
involvement in early stages of carcinogenesis and can lead to downregulation of further genes 
such as PTEN. PMS2 and MHL1 have been previously determined as causative genes in LS 124. 
MLH1 methylation is implicated as the primary cause of microsatellite instability (MSI) in 
sporadic endometrial cancers 125. Kanopiene et al., observed through investigation of 109 
endometrioid endometrial cancers that MSI high tumours were related to more aggressive 
clinicopathological parameters including higher histological grade and therefore, deeper 
myometrial invasion in comparison to MSI stable tumours 126. This was witnessed in these 
patient samples as patient GB#13 had deeper myometrial invasion than other GB#16 and 
GB#23 patients. MSI hypermutated tumours are usually later stage cancers127, which is what is 
observed as GB#13 had a diagnosis of stage IIIB, while both GB#16 and GB#23 patients had 
stage IB cancers (Table 5). 
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The results from patient GB#13 in the current study show very high ΔCt mRNA expression 
(>15) of SOX17, ANO1, SATB2, KLF4 and ER in GB#13R cells while relative expression of 
ANO1, SATB2, KLF4 and ER were not detectable in the GB#13S cells. Loss of MMR genes 
are known to increase rates of spontaneous mutations, due to increasing the rate of gene 
duplication by 50-100 fold 128. The difference in the ΔCt mRNA expression between LNG 
sensitive and LNG resistant cells is due to the addition of LNG as the parent cells have the same 
genetic background, and therefore only differ in their mechanism of LNG resistance. However, 
it would be interesting to investigate the effect of MLH1 methylation on increased gene 
expression in resistant cells, as the same level of upregulation was not observed in the GB#16 
of GB#23 primary cultures.   
Patient GB#16 had a clinical diagnosis of grade 3, stage IB clear cell EC. The diagnosis of 
early-stage cancer made this patient relevant for the current research. The molecular subtyping 
of this patient showed P53/P16 overexpression alongside wt1 (-), napsin A (-), ER (-), HBM E-
1 (-) vimentin (+) staining. This staining is classically associated with higher grade tumours 129, 
such as the clear cell grade 3 EC that this patient was diagnosed with.  
Patient GB#23 was an ideal candidate for the current study. This patient was diagnosed 
clinically and pathologically with grade 1, stage IB endometrioid carcinoma, and was MSI 
stable. Pelvic lymph node dissection was not performed due to technical challenges of the 
surgery such as elevated BMI and difficulty with ventilation. This woman would be a prime 
candidate for Mirena® therapy following biomarker analysis as the comorbidities associated 
with this patient prevented the optimal surgical approach from occurring.   
4.3.1 Optimisation of primary tissue culture 
Patient tissue samples were collected at the time of surgery and processed immediately. For the 
GB#13 sample, following digestion, cells were cultured in a tissue culture flask. Due to this 
being the first sample for optimisation, the separation of cancer associated stromal cells from 
adenocarcinoma cells was not carried out and the cells cultures were heterogenic in nature. RT-
qPCR was then a direct representation of all cell types present in the tissue. Following collection 
of the second sample, the separation of cancer associated stromal cells from adenocarcinoma 
cells was carried out using a 40µm cell strainer, which has proven efficacious for this process 
in previous studies 130. This separation was carried out on the second samples as the 
adenocarcinoma cells are significant for investigating ΔCt mRNA expression in the current 
study. Alongside this, 3D modelling of primary cultures may be carried out, or the effect of 
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LNG may be explored in both epithelial and stromal cells in the future. Therefore the process 
of cell type segregation was important to optimise. It was noted for the GB#13 sample that the 
epithelial cells did not adhere as efficiently as the stromal cells, and therefore had difficulty 
reaching confluence. Due to this observation, for the third sample GB#23, the epithelial 
adenocarcinoma cells were cultured in a smaller flask precoated with collagen to assist in 
adherence. It would be beneficial in future studies to carry out immunocytochemistry stains 
such as CK7, CK8, vimentin, PTEN in epithelial cells, or IHC on stromal cells using CD10 or 
IFITM1 131. Flow cytometry and relevant cellular markers to assess the population of the cells 
in tissue samples prior to RT-qPCR analysis may also be used. At this time, this has been done 
through observation of the morphological characteristics of the cells, however, I do not believe 
an accurate separation of the cell types was achieved due to limited morphological differences 
between the ‘cancer associated stromal cells’ and the ‘adenocarcinoma cells’. (Appendix 2, 
Figure S2). 
All primary cell lines were split upon confluence into Primary resistant cells (PR) and Primary 
sensitive controls (PS). A kill curve of 0-300µM LNG was carried out on the GB#13 cell line 
to determine the optimal treatment concentration range for primary cells. (Appendix 3, Figure 
S3). All three primary cell lines were treated with 100 µM LNG to begin with, however as the 
cells became more resistant to the treatment (usually following 2 weeks of treatment) the dose 
was increased to 200µM LNG. Primary cells are only able to be passaged up to four times (P4), 
therefore, complete resistance was difficult to achieve, however the qPCR results display an 
obvious difference between the PR cell line and PS cell line.  
4.4 Determination of LNG resistance  
The development of resistant cells was vital in this study to understand the potential 
mechanisms of resistance to LNG and identify the behavioural and genetic differences between 
LNG resistant cells and LNG sensitive cells. Only one study 6 has previously established 
progesterone resistant EC cell lines. This particular study developed MPA resistant Ishikawa 
cells for microarray analysis of DEGs. To develop this line, cells were treated with MPA at 
escalating doses from 1µM to 10µM. Once the proliferation of the progesterone resistant cells 
was the same as that of the control cells, a stable progesterone resistant Ishikawa cell line was 
said to be achieved 132. For the current study, an initial IC50 was carried out to determine the 
concentration to treat the cells in order to develop resistance. Initially, the IC50 ranged from 0-
100µM LNG, which gave a final cellular viability of 86% at 100µM for the MFE296 cell line 
and 64% at 100µM for the MFE319 cell line. Therefore, a second IC50 was carried out that 
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ranged from 0-500µM. From this, the point at which 30% cell viability was observed was 
chosen to treat the cells. The MFE296R and MFE319R cells were constantly treated every two 
days with this concentration of LNG with no escalation. Resistance was then assessed via a 
second IC50. The IC50 values of MFE296S and MFE296R cells were 250µM and 1800µM 
respectively, and the fold change increase in resistance from MFE296S and MFE296R was 6. 
The IC50 values of MFE319S and MFE319R cells were 250µM and 2000µM, respectively, and 
the fold change increase in resistance from MFE319S and MFE319R was 8. Due to increased 
variation in triplicates within the MFE296 cell line, the fold change in resistance was 
challenging to determine, and may not be the most accurate representation of a change in 
resistance. In this study, the rate of proliferation was the same between the resistant cell lines 
and sensitive controls, therefore these results, and the literature 133, assisted in determining that 
a stable LNG resistant cell lines had been reached.   
Development of a clinically relevant drug-resistant cell line can take anywhere from three to 18 
months 120. A clinically relevant drug resistance model is one that is associated with a 2-5 fold 
increase from the IC50 in the parent cell line and these cells lines are developed to mimic the 
conditions of traditional cancer treatment 120. This is achieved through treating the cells with 
lower doses coupled with pulsing mechanisms over an extended time period, and allowing the 
cells to recover in media free from the drug 120. While this method may have made the current 
study more clinically relevant, the disadvantages associated with the development of these lines 
such as unstable resistance, low resistance levels and smaller molecular changes to analyse 120 
would have made it challenging to develop in the given time period. Instead, I developed a 
high-level laboratory model 120. To develop this model in a shortened time period of three 
months, the dose of LNG chosen to treat the cells was high (conventional treatment ranges from 
drug concentrations that cause 20-50% cell viability)120. This is because the honours year was 
shortened due to COVID-19 and the cells needed to show a level of resistance to continue on 
with the current study. It was important that the concentration chosen was not too high, at risk 
of not having sufficient cells to successfully culture, or too low, that the population residing 
following treatment contained a high number of non-resistant cells. High level laboratory 
resistance models give rise to more stable, higher levels of resistance and therefore the 
molecular changes associated with resistance are more apparent in a shorter time frame 120. In 
saying this, due to the high level of resistance in these cells, it can decrease the clinical relevance 
of the research. However, this is a pilot study with the aim of identifying apparent molecular 
differences associated with LNG resistance, and clinical relevance is not the first priority in 
early studies. It would be interesting to compare the level of LNG resistance in early-stage 
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endometrial cancer patients treated with the Mirena® and the level of resistance achieved in 
my study, however, this information is not yet available.  
Concerning the clinical relevance of LNG concentrations, the Mirena® releases LNG at an 
average rate of 15g daily over five years 134.  LNG is detectable in the serum immediately 
following insertion, with the maximum serum concentration reached after two weeks 134. For 
the first 6 months, serum concentrations are 151pg/mL to 264pg/mL on average, and this 
declines to 113pg/mL to 161pg/mL on average after 5 years 134. For the current study, MFE296 
cells were treated with 450M LNG, and MFE319 cells were treated with 350M LNG. This 
works out to be 30g/mL, over 1000 times higher than the physiological concentration. 
However, the aim of this study was not to mimic in vivo treatment with the Mirena®, but to 
create a model of the intrinsically LNG resistant EC cells that reside in women that are not 
responding to the Mirena®.  
4.5 Behavioural analysis of LNG resistant cell lines.  
Increased proliferation, migration, invasion and decreased adherence are all implicated in the 
EMT process. EMT is a physiological process involved the early stage of carcinogenic 
dysregulation 135,136. During this process, cells begin to lose epithelial characteristics and 
acquire mesenchymal characteristics such as increased motility through the reprogramming of 
gene expression 135. Acquisition of EMT phenotype has been previously associated with drug 
resistance, which could make these tumours more likely to metastasise or recur following 
treatment 137. This is consistent with the results from the current study show that the LNG 
resistant cells may be slightly more aggressive, and have more EMT potential than their LNG 
sensitive counterparts. Clinically, this research is warranted as it is the first time the behavioural 
profile of LNG resistant cells has been investigated. It was vital to understand if LNG resistant 
cells behave differently as this could lead to different treatment pathways for women who are 
resistant to the Mirena®, further demonstrating a need to identify these non-responders prior to 
treatment. To determine whether cells have undergone EMT, expression of markers such as 




4.5.1 LNG resistance has minimal effect on cell proliferation in immortalised 
cell lines. 
Increased proliferation beyond the cells natural life span is a characteristic that malignant cells 
adopt during the process of early carcinogenesis 136.  Li et al., described stable resistance as the 
proliferation rate of the progesterone resistant cells being the same as that of the control cells 
132. For the current study, the same rate of proliferation between LNG resistant cells and LNG 
sensitive cells was vital in determining stable resistance in the MFE319R and MFE296R cell 
lines. The results of the current study show that there is no significant change in proliferation 
between the LNG resistant lines and the LNG sensitive cells, apart from the significant increase 
in MFE319R cells at the 48h time point.  
While in vitro tumour models have provided important tools for cancer research, it is impossible 
to capture the tumour heterogeneity in vitro therefore while the current findings show minimal 
difference in the proliferation of resistant cells compared to control cells, it is impossible to say 
the same would be observed in LNG resistant cells in EC patients. More recently, markers of 
proliferation such as Ki67 83 has been used to determine the rate of proliferation in non-
responders compared to responders treated with the Mirena®. Alongside this, increased 
expression of Cyclin A has also been identified as a reliable marker of increased proliferation 
in endometrial cancer cell lines140. These markers could serve as a non-invasive method to 
monitor proliferation in vivo. 
One limitation of this method is that CCK8 is a cell viability dye, and can therefore not 
distinguish between growing metabolically active cells, and senescent metabolically active 
cells. Senescent cells will still convert the dye and will therefore contribute to the overall 
absorbance of cells at different levels. The LNG resistant cells may have had a higher overall 
population of senescent cells, which could have appeared as if the cells were proliferating at 
the same rate, but overall, the LNG resistant cells may have been proliferating slower than the 
LNG sensitive cells which would have been more consistent with what I observed during the 
process of culturing the cells. There is a pre-assumption associated with this experiment where 
all remaining surviving cells subsequent to LNG treatment are proliferating. Without other 
identification methods, we cannot however prove this. Identification characteristics such as a 
flat, large morphology and increased senescence-associated β-galactosidase activity can be 
used to differentiate between cells that reside in senescence and normal cells. Identification of 
these characteristics in vitro is critical to monitor cell changes from a spindle-like to a flattened 
morphology to the mentioned morphology above 141, to ensure that the cells are senescent. 
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Therefore, viewing the gross morphology of the cells alongside fluorescence should also be 
considered in future studies 141 
4.5.2 LNG resistance has some effect on Migration 
Metastasis is a multistep process including proliferation, migration and invasion in malignant 
cells. Therefore, investigating the capacity of LNG-resistant cells to migrate in vitro is 
important in developing a behavioural profile of these cancer cells 142. Transwell migration is 
the process where cells pass through a transwell membrane into a chemoattractant, analogous 
to a leaky endothelium into the blood stream in vivo 143. This is a high throughput assay which 
can be used to compare the metastatic potential of LNG resistant cells and their control 
counterparts 144. In this study, there was no significant increase in migration between MFE296R 
cells and MFE296S cells, however, migration was increased in MFE319R cells compared to 
MFE319S cells, seen by an increased number of cells. Typically, in the literature, a 30-80% 
reduction in migration is observed when treating cells 145-147, however, the effect of 
progesterone resistance on migration in endometrial cancer cells has yet to be evaluated, apart 
from in the current study.  
A transwell assay is a useful in vitro tool, however, measuring cellular migration in two-
dimension (2D) lacks physiological relevance due to its ability to only investigate single cell 
motility, providing misleading and non-predictive data for a response in vivo 144,148. For a better 
physiological understanding, a three-dimensional (3D) migration model would be beneficial 
144.  Activated leukocyte adhesion molecule (ALCAM) has been identified as a marker of 
recurrence in EC, however has demonstrated potential in vitro as a marker of cell migration and 
invasion in early stage tumours 149. This could therefore be a useful marker to investigate in 
LNG resistant and LNG sensitive cells to monitor their capacity to migrate. This marker could 
also be beneficial clinically as a non-invasive way to monitor migration of the tumour cells 
when undergoing treatment with the Mirena®.    
There are two main types of cancer cell migration; collective cell migration and individual cell 
migration 150, 151. Collective migration can be described as connected cells moving as a whole, 
while individual cell migration is when singular cells invade and migrate to surrounding tissues 
independently of each other 150. Collective cell migration has been previously observed in EC 
development, which can be seen as cells moving 2D sheets in vitro 150.  A wound healing assay 
investigates the ability of the cells to migrate following exposure to a cell free area (scratch) 
which induces the cells to migrate into this area 152.  
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When carrying out the 2D wound healing assay in the current study, in both cell lines, collective 
migration was observed in both MFE296 and MFE319 cell lines. This was conserved across 
both resistant cell lines and control cell lines, indicating that LNG resistance had no effect on 
the nature of migration of the cells. 2D would healing assays can have reduced accuracy, due 
to relocation of exact scratch points without live cell imaging 152. Another limitation of scratch 
assay analysis is the measurement process, as the scratch will have jagged edges 152. This was 
overcome in the current study using Tscratch (CSE lab software) which automatically analyses 
the monolayer wound healing assays, and allows for manual adjustments if required. This 
software is highly reproducible and more accurate than traditional measurement methods 153.   
It is often stated that the proliferative rate of the cell lines would affect migration, however, the 
LNG sensitive cells migrated at the same rate as the LNG resistant cells therefore while this 
was a factor for the differing proliferative rate of MFE319 and MFE296 cells (MFE 296 cells 
have a much faster doubling rate) the proliferation would not have effected migration or 
invasion of the cells. However, it is not known the effect that senescent cells or the cessation of 
cellular growth could have has on LNG resistant cells, due to the limitations of CCK8 in the 
proliferation assay. In saying this, the decreased adherence of the LNG resistant cells in both 
cell lines may have affected migration, as the cells settled with gaps, making it difficult to create 
a scratch in fully confluent cells and making measuring “% open area” more complicated. 
Migration assays can be desensitised to proliferation through the use of lineage-tracing vital 
stains 154. The original cells are stained, therefore the stain is retained and diluted through cell 
generations and migration is calculated relative to the original, parental cell population 
154. Inhibitors of proliferation such as Mitomycin-C can also be used to develop a model of 
migration that is unaffected by the confounding influence of cell proliferation 155. 
4.5.3 LNG decreases cell invasion in MFE296 cells but increases invasion in 
MFE319 cells.  
Invasion is another key hallmark of malignant tumours 156. Physiologically, tumour cells invade 
through basement membranes and into the ECM through invadopodia, which are structures 
enriched with active filaments and adhesion proteins to degrade the ECM 157, 158. There are 
many ways to measure invasion in vitro, including the Boyden chamber assay, with an added 
collagen/Matrigel layer, however, the assay used in the current study was a 3D tumour spheroid 
invasion assay which is a highly reproducible in vitro invasion model 156. Cells are able to 
invade from the body of the spheroid into a surrounding matrix containing type one collagen 
and Matrigel. This invasion assay was chosen as it has a standardised method well described in 
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the literature, and compared to monolayer 2D studies, the spheroid arrangement of cells creates 
a more physiologically relevant in vitro model of a tumour 156.  
Again, cell markers such as Activated leukocyte adhesion molecule (FN1) and cyclin D1 
(CCND1) have been previously implicated in cancer invasion in low grade endometrioid EC 
159. Increased protein expression of these two markers correlated with more aggressive cell 
behaviour including lymph node metastasis 159. This prediction method called the MDACC test 
set, and can indicate histological grade, FIGO stage and myometrial invasion 159. ALCAM has 
also been identified as a marker of cell invasion 149. These markers could therefore be a good 
way to monitor invasion in early stage EC samples in vitro or in vivo.  
There are many different patterns of invasion that can be observed from this particular type of 
assay. These include the typical starburst invasion pattern, where the extending pseudopodia 
are very evident and the budding pattern, where cells appear to ‘bud’ out of the central spheroid 
rather than projecting out in the form of pseudopodia 156. The main stated limitation for this 
assay is the inability to distinguish between the invasion of cells, and the proliferation of the 
cells within the spheroids 156. The spheroids are monitored for invasion over a period of 96 
hours. The doubling rate of MFE296 cells is 25.1 hours, and the doubling rate for MFE319 cells 
is 41.4 hours 123 therefore, during the observation period, the cells will have sufficient time to 
proliferate substantially. In the current study, a more expansive, budding growth pattern of the 
spheroids was seen, rather than a conventional infiltrative invasion pattern 156. However, again, 
the lack of knowledge around senescent cells in the LNG resistant population limits the ability 
to ensure the LNG resistant cells and LNG sensitive cells were proliferating at the same rate. 
This does not explain the opposite phenomenon observed in the cell lines, in saying this, due to 
the 3D spheroid invasion assay only being an n=1, the significance of the results cannot be 
commented on. Again, it would be interesting to develop an invasion assay desensitised to 
proliferation  through the use of lineage-tracing vital stains 154 or proliferation inhibitors as 
mentioned above, to determine if the same results will be observed independent of the 
proliferative rate of the cells.  
While this form of assay claims to be highly reproducible, it was difficult to develop spheroids 
of the same size across both cell lines. Due to the higher doubling time of the MFE296 cells, 
when left for the same time periods to grow, the MFE296 spheroids were much larger than the 
MFE319 spheroids. This may have caused the difference in the invasion of respective cell lines. 
The sizes of spheroids embedded into the matrix were highly variable in both cell lines, and 
there was breakage of spheroids and debris when plating the MEF319 spheroids into matrigel, 
which again, may have affected the ability of these spheroids to invade.  
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4.5.4 LNG decreases cell adhesion in immortalised cell lines.  
Loss of adherence is an important step in tumorigenesis. Cells lose their original tissue contacts, 
allowing them to move and progress through the extracellular matrix and metastasise around 
the body 160, a vital part of EMT. The 2D assay used in the current study, measures the ability 
of the cells adhere to proteins in the extracellular matrix, in this case, type I collagen which is 
the most abundant protein in the ECM physiologically 161. Changes in the way cells interact 
with ECM proteins can influence and control cell behaviour, therefore adhesion was vital to 
investigate in the behavioural profile 162. Fibronectin and laminin are both ECM proteins that 
are commonly used in adhesion assays, so to strengthen the assay used in the current study, it 
would have been good to further investigate the adherence of these cells to further ECM 
proteins. Matrix Metalloproteases (MMP) are proteins that break down the ECM surrounding 
the cells to facilitate metastasis 163. MMPs are able to do this through targeting adhesion 
receptors on tumour cells including E-cadherin and integrins 164. MMP transcriptional 
expression can be induced through tumour specific mechanisms such as EMT 164. Increased 
MMP expression has been previously linked with biologically aggressive EC165, therefore it 
would be interesting to measure the MMP levels in LNG resistant cells compared to LNG 
sensitive cells to identify if the decreased ability to adhere to ECM proteins is attributed to 
increased MMP expression.  
The current study observed decreased adherence in LNG resistant cells after one hour. The one 
hour time point was optimised and chosen due to the cells being too adherent at the three hour 
time point, seen through adherence to the negative control, BSA.  
Reactive oxygen species (ROS) are a consequence of apoptosis in cell culture 166. Due to the 
LNG resistant cell lines not being 100% resistant, and therefore, having increased levels of cell 
death (apoptosis) there will most likely be increased levels of ROS in cell culture. This induces 
oxidative stress. While the effect of oxidative stress has not been studied in endometrial cancer 
cells, it has been seen to inhibit adhesion in pluripotent stem cells 166. Interestingly, in human 
decidual endometrial stromal cells, expressions of FOXO1 could be promoted by 
dihydrotestosterone (DHT) to enhance the resistance to oxidative stress 167. This was a gene 
studied in these cells, however, while MFE296 cells showed an increase in FOXO1, this 
observation was not significant and the same was not seen in MFE319 cells, therefore, these 
cells may have not developed resistance mechanisms to oxidative stress, inhibiting their ability 
to adhere, and playing an important role in the pathogenesis of those cells 167. 
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4.5.6 Conclusions from behavioural analysis  
Overall, what was seen consistently across both cell lines is that LNG resistance had no effect 
on the proliferation of MFE296 and MFE319 cell lines. LNG has no effect on wound migration, 
but increased migration in MFE319 wells, however, the same was not seen in MFE296 cells. 
LNG resistance led to both MFE296R and MFE319R cell lines having decreased adherent 
abilities. The significance of invasion cannot be commented on due to biological triplicates not 
being carried out. These observations lead to the hypothesis that “LNG resistant cells will 
behave differently to LNG sensitive cells” to be accepted.  Some significant behavioural 
changes were witnessed, however, most were not conserved across both cell lines. The 
differences in the oncogenic potential of LNG sensitive and LNG resistant cells is very 
complex, and should be investigated further. It is difficult to determine if the behavioural 
differences are a direct result of the LNG resistance mechanism adopted by the cells, or a result 
of the increased cellular stress MFE296R and MFE319R were subjected to. Further studies that 
investigate the levels of ROS in culture would be able to confirm this.  
4.6 LNG resistant cells express different levels of mRNA to controls. 
The current study observed significantly increased expression of CRISPLD1, KLF4, SATB2, 
SOX17, ANO1 and HE4 in resistant cell lines (MFE296R and MFE319R). RT-qPCR remains 
the most sensitive and specific technique for the detection of often-rare mRNA targets 168. The 
generation of a melt curve during the process of RT-qPCR allows for the confirmation that the 
fluorescence signal is generated only from the target mRNA templates and not from non-
specific PCR products 169. This was beneficial during the process of primer optimisation as 
while a strict primer design protocol was followed, some primers still had off-target binding. 
The melt curve analysis allowed specific primers to be chosen to most accurately represent the 
mRNA levels of chosen genes. 
4.6.1 Ct value significance 
CRISPLD1, KLF4, SATB2, SOX17, ANO1 and HE4 were all identified as significant DEG’s 
in this study. Ct values of < 29 are strong positive reactions indicative of abundant target nucleic 
acid in the sample Ct values of 30-37 are positive reactions indicative of moderate amounts of 
target nucleic acid Ct values of 38-40 are weak reactions indicative of minimal amounts of 
target nucleic acid. All of the DEG’s identified in the current study except for SOX17 were 
associated with moderate to strong expression results and therefore, can be deemed relevant. 
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The Ct values from these samples are important to identify a biomarker that can be deemed 
clinically relevant.  KLF4 across all cell lines and HE4 in both MFE319S and MFE319R cell 
line were associated with the lowest overall Ct values.  
4.6.2 Key findings from mRNA analysis  
Expression of CRISPLD1, KLF4, SATB2, SOX17, ANO1 and HE4 were significantly 
upregulated in resistant cell lines (MFE296R and MFE319R) compared to LNGS controls. 
(Figure 21A-F). All three primary cell lines showed increased mRNA expression of KLF4 in 
LNG resistant cells compared to LNG sensitive cells.   
These results suggests that these genes may be implicated in LNG resistance and thus serve as 
predictive biomarkers for response to the Mirena®. This section will discuss each gene and 
their relevance in the field of EC. 
4.7 Cellular hormone receptor expression as predictive biomarkers in 
endometrial cancer 
Alongside the six DEGs identified in both MFE296 and MFE319 cell lines, the relative mRNA 
expression of hormone receptors ER and PR was measured in the current study. Low expression 
of PR99-101, 114 and high expression of  ER100, both protein and mRNA, have been shown in the 
literature to predict a negative response to progesterone treatment. In the current study, all three 
primary cell lines showed a decrease in the Progesterone receptor, however the same 
observation was not made in the immortalised cell lines. Both the GB#13R and GB#23R cell 
lines showed an increase in the relative mRNA expression of ER compared to LNG sensitive 
cells, while GB#16R cells had increased relative mRNA expression of ER. Research has shown 
that Mirena® treatment can lead to a down regulation of nuclear PRs 170. This indicates that 
despite previous research showing PR to have potential to predict negative response to 
treatment, PR would not make an efficacious predictive biomarker due to its expression being 
somewhat reliant on treatment. Alongside this, the two main subtypes of PR, PR-A and PR-B 
have been said to have opposing roles in estrogen induced endometrial proliferation 171. PR-A 
has been said to inhibit proliferation, while PR-B contributes to it. The two receptor subtypes 
are also very difficult to differentiate via immunohistochemistry (IHC). The current study only 
investigated PR-B expression, therefore it would be beneficial to use RT-qPCR to investigate 
both subtypes further. Expression of hormone receptors should be investigated in larger cohorts 
of women to understand the effect that Mirena® treatment has on receptor expression.  
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4.8 Cellular KLF4 expression as a predictive biomarker in endometrial 
cancer  
4.8.1 Current and previous findings  
KLF4 is a member of the zinc finger containing Krüppel-like factor family 172. It is involved in 
the regulation of diverse physiological functions and cellular processes such as cellular growth, 
proliferation, differentiation and somatic cell reprogramming 172. KLF4 has been identified to 
play an important role in the pathogenesis of many cancers 172. RT-qPCR was performed to 
understand the predictive potential of KLF4 in early-stage EC patients undergoing Mirena® 
treatment. The current finding is that the relative expression of KLF4 is significantly increased 
in both MFE319R cells and MFE296R cells in comparison to the respective controls. KLF4 was 
also increased in the GB#13R, GB#16R and GB#23R primary samples compared to sensitive 
controls. The relative mRNA expression of KLF4 within both immortalised cell lines was high 
and ranged from 1.0 to 4.1 in LNG resistant cells compared to 0 – 0.7 in the immortalised 
control cells. Strikingly, KLF4 relative mRNA expression was noted as 17.57 in the GB#13R 
cells, and non-detectable in the control cells.  
KLF4 has not previously been investigated as a predictive biomarker to Mirena® treatment. 
KLF4 mRNA expression however has been previously observed to increase in the presence of 
progesterone receptor agonists such as progesterone and dienogest (synthetic progestin) in 
human endometrial epithelial cell lines 173. This is consistent with the current study where we 
see an increase in KLF4 relative mRNA expression in resistant cells, however the cells used in 
the current study were endometrial cancer cell lines, compared to non-cancerous human 
endometrial epithelial cells.   
4.8.2 Functional relevance of KLF4 in endometrial cancer  
KLF4 is a Wnt pathway antagonist. Wnt signalling governs proliferation and survival, 
therefore, a decrease in proliferation, survival and migration should be witnessed in LNG 
resistant cells 173. This was not seen however, possible due to the involvement of KLF4 in other 
molecular pathways. The only way to know if Wnt signalling is truly downregulated in these 
cell lines is through carrying out a TOP-FLASH Wnt reporter assay, a luciferase assay to 
measure β-catenin activity in vitro 174. KLF4 promotes survival through suppression of BAX175 
and TP53176. This was obviously seen in the LNG resistant cells through their ability to resist 
cell death following LNG treatments.  KLF4 acts as a stem cell factor promoting EMT in 
endometrial cancer, therefore indicating that higher expression of KLF4 in cells should 
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correlate to an increase in cellular invasion, survival and proliferation 172. Obviously an increase 
in survival was observed in the LNG resistant cell lines compared to the LNG sensitive, 
however as mentioned, the proliferation rate between LNG resistant cells and LNG sensitive 
cells does not differ indicating that proliferation was not dependant on KLF4 itself.  
 KLF4 has previously been shown to inhibit the MAPK pathway 173. Inhibition of the MAPK 
pathway has been shown to increase nuclear PR protein 177, and increased PR expression 
increases responsiveness to progesterone therapy 99-101, 114. MAPK inhibitors have been seen to 
have the same antagonistic effect on PR receptors than specific PR antagonists themselves, 
proving that the MAPK pathway is a potent inducer of PR phosphorylation 178. Exposure to 
progestin therapy has also been shown to transcriptionally silence PR expression, meaning LNG 
would have has no effect on the cells 178. While there was no significant difference in the PR 
expression of LNG resistant and LNG sensitive cells, this relationship should be investigated 
further as it could be a mechanism of resistance in the LNG resistant cells. The potential 
mechanism is displayed in (Figure 25). 
Transcription repression of FOXO1 by KLF4 has been implicated in the progression of glioma 
179. The relationship between FOXO1 and KLF4 is interesting as downregulation of FOXO1 
mRNA levels have been shown to predict a negative response in EC and endometrial 
hyperplasia patients managed with the Mirena® 114. However, in this study, while upregulated 
expression of KLF4 is seen, a significant decrease in FOXO1 is not seen. The relationship 
between KLF4 and FOXO1 should be further investigated in this context of endometrial cancer. 
(Figure 25). 
4.9 Cellular HE4 expression as a predictive biomarker in endometrial 
cancer  
4.9.1 Current and previous findings  
HE4 is one of many WAP proteins 180, which are proteins involved in protease inhibition that 
function in protective immunity 181. HE4 is commonly overexpressed in many cancers and 
detectable in 90% of early-stage ECs via ICH 133. To investigate the expression of HE4 in 
resistant and control EC cells, RT-qPCR was performed. Comparable to previous findings 105, 
106, the current study found that relative HE4 mRNA expression was significantly increased in 
resistant cell lines compared to respective controls. Both immortalised cell lines showed a 
relative mRNA expression of >1 in LNG resistant cells. This expression was high and ranged 
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from 1.3 to 3.1 in resistant cell lines compared to 0 – 0.9 in the control cells. HE4 relative 
mRNA expression was also upregulated in GB#16R and GB#23R patient samples compared to 
controls.   
Previous studies have investigated HE4 as a predictive biomarker 105, 106. Behrouzi et al., found 
that higher levels of serum HE4 during and following treatment indicate a negative response to 
treatment in early-stage EC and atypical hyperplasia 105.  Orbo et al., found that an increase in 
the expression of HE4 during and following progestin therapy regimens can predict a negative 
therapy response, indicating progestin resistance for medium and low risk endometrial 
hyperplasia. Interestingly, Orbo et al., found this in tissue samples, unlike Behrouzi et al., who 
found that HE4 was only relevant in serum samples 105. This is the first time HE4 has been 
investigated as a potential predictive biomarker in the context of endometrial cancer cells 
(originating from tissue) using qPCR. Previously, HE4 expression has been determined using 
both IHC and ELISA to identify the associated protein levels of HE4 in the blood. The same 
results were however found, HE4 is increased in LNG resistant cell lines.  
4.9.2 Functional relevance of HE4 in endometrial cancer  
Studies have shown that elevated serum HE4 correlates positively with advanced age, 
menopause, higher FIGO stage and grade, greater tumour size, deep myometrial invasion, 
lymph node involvement and reduced survival 182-184. Unfortunately, due to the lack of primary 
cell samples in the current study, the relevance of this clinicopathological features could not be 
investigated. HE4 has been previously identified as a prognostic marker in EC, following its 
success as a pre therapeutic prognostic marker in ovarian cancer 182, 184. Li et al., observed that 
expression of HE4 increased with a decrease in the degree of differentiation 185 leading to the 
observation that EC patients with high HE4 expression have a poor prognosis 185. This could 
indicate again that women that are resistant to LNG may also have a poorer prognosis, and a 
higher level of differentiation within their tumour cells, however this would have to be further 
investigated in a larger patient cohort.  
4.10 Cellular SOX17 expression as a predictive biomarker in 
endometrial cancer  
4.10.1 Current and previous findings  
SOX17 is a regulator of many developmental processes and disease progression. SOX17 had 
previously been investigated for its role in progesterone resistance in EC. Li et al.,  identified 
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SOX17 as being significantly enriched in a progesterone resistant cell line, compared to 
controls 6. Comparable to previous findings 6, the current study found that relative SOX17 
expression was significantly increased in resistant cell lines compared to respective controls. 
Both immortalised cell lines showed a relative mRNA expression of >1 in LNG resistant cells. 
This expression was high and ranged from 0.8 to 2.25 in resistant cells compared to 0 to 0.9 in 
the control cells. SOX17 was also upregulated in GB#13R and GB#23R patient samples 
compared to controls. Interestingly, MFE296S did not express SOX17 at a level detectable by 
qPCR.   
4.10.2 Functional relevance of SOX17 in endometrial cancer  
SOX17 is reportedly mutated in 8% of ECs and has been previously identified as a mutated 
driver of EC though tumour suppressor activity 186,187. This is interesting as ΔCt mRNA 
expression of SOX17 was extremely low in LNG sensitive controls and increased in LNG 
resistant cells, however the current study only measured the mRNA expression of SOX17 in 
EC cells, and did not investigate the mutational status of SOX17. SOX17 is a Wnt pathway 
antagonist through inhibition of β-catenin 188. SOX17 has shown to inhibit tumour migration, 
proliferation and invasion leading to increased levels being associated with better prognosis in 
EC type II patients 189. The same however was not observed in type I endometrial cancer cells 
in the current study as proliferation was not increased in LNG resistant cells, and the invasion 
and migration across LNG resistant cells was inconclusive.  
Decreased SOX17 levels may promote EC development and progression through decreased 
tumour suppressor activity, however the function of SOX17 in endometrial cancer is still 
unclear 188. The potential mechanism of SOX17 in LNG resistance can be seen in (Figure 25). 
Interestingly, genome wide profiling has implicated SOX17 as it is a direct transcriptional PR 
target and is upregulated by progesterone in mice uterine epithelium 190. This would explain the 
increase in SOX17 in the LNGR cells, however this relationship has not been investigated in 
humans.  
4.11 Cellular ANO1 expression as a predictive biomarker in 
endometrial cancer  
4.11.1 Current and previous findings  
ANO1 is frequently amplified in human cancers 191 and has previously been investigated for its 
role in progesterone resistance in EC. Li et al., identified ANO1 as being significantly enriched 
67 
 
in a progesterone resistant cell line, compared to controls 6. Comparable to previous findings 6, 
the current study relative ANO1 relative mRNA expression was significantly increased in 
resistant cell lines compared to respective controls. Both immortalised cell lines and the GB#13, 
patient sample showed a relative mRNA expression of >1 in LNG resistant cells. This 
expression was high and ranged from 1.8 to 3.9 in resistant cells compared to 0.1 to 0.7 in the 
control cells. Alongside this, ANO1 was also upregulated in GB#16R cells compared to the 
control.  
4.11.2 Functional relevance of ANO1 in endometrial cancer  
Information about the functional relevance of ANO1 in endometrial cancer is limited. Wang et 
al., have previously identified high expression of ANO1 as an individual positive prognostic 
marker of endometrial cancer 191. Wang et al., also observed ANO1 mRNA expression to be 
significantly associated with age, histological type, clinical stage, pathological grade and 
positive peritoneal washing in EC 191. ANO1 was also implicated in various pathways, 
including metabolic pathways 191.  
Interestingly, ANO1 is required to sustain glucose-stimulated insulin secretion 192. Insulin 
resistance leads to higher levels of insulin, and these high levels have been proven to contribute 
to the development of EC through directly promoting cell proliferation and survival through 
the PI3K/Akt and Ras/MAPK pathways 193. As mentioned previously, inhibition of the MAPK 
pathway has been shown to increase nuclear PR protein 177, and increased PR expression 
increases responsiveness to progesterone therapy. (Figure 25). This is interesting that ANO1 
has significantly increased relative mRNA expression in the LNG resistant cells 177, 194. This 
relationship may have contributed to the behavioural differences that were witnessed between 
LNG resistant and LNG sensitive cells and therefore, should be investigated further.  
4.12 Cellular CRISPLD1 expression as a predictive biomarker in 
endometrial cancer  
4.12.1 Current and previous findings  
CRISPLD1 previously been investigated for its role in progesterone resistance in EC. Li et al., 
identified CRISPLD1 as being significantly enriched in progesterone resistant cell lines, 
compared to controls 6. Comparable to previous findings 6, the current study found that relative 
CRISPLD1 relative mRNA expression was significantly increased in LNG resistant cell lines 
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compared to respective controls. Both immortalised cell lines a relative mRNA expression of 
>1 in LNG resistant cells. This expression was high and ranged from 0.8 to 2.2 in resistant cells 
compared to 0 to 0.6 in the control cells. CRISPLD1 was also upregulated in GB#16R and 
GB#23R cells compared to controls.  
4.12.2 Functional relevance of CRISPLD1 in endometrial cancer  
Little information surrounds the implication of CRISPLD1 in endometrial cancer, however, it 
was chosen for this study due to it being previously upregulated in progesterone resistant 
Ishikawa endometrial cancer cells 6. CRISPLD1 is implicated in the regulation of extracellular 
matrix and in cellular adhesion during the fertilization process 195, and alongside other CRISP 
genes is highly expressed in the reproductive tract and in many cancers 195. CRISPLD1 is also 
noted as a downstream target of progesterone receptor A 195, which could explain why 
CRISPLD1 is increased in cells subjected to constant progestin exposure, as progesterone has 
been proved to induce progesterone receptor gene expression 196.  
4.13 Cellular SATB2 expression as a predictive biomarker in 
endometrial cancer  
4.13.1 Current and previous findings  
SATB2 is a nuclear matrix‐associated transcription factor that is associated with abnormal 
expression in certain cancers but has not been reported for endometrial cancer 197. The current 
study observed that relative SATB2 relative mRNA expression was significantly increased in 
resistant cell lines compared to respective controls. Both immortalised cell lines and the GB# 
13 and GB#16 patient samples showed a relative mRNA expression of >1 in LNG resistant 
cells. This expression was high and ranged from 1.0 to 3.5 in resistant cells compared to 0.1 to 
0.9 in the control cells.  
4.13.2 Functional relevance of SATB2 in endometrial cancer  
Again, limited information is available on the relevance of SATB2 to endometrial cancer. This 
particular gene was chosen for this study due to its prognostic value in endometrioid ovarian 
cancer. Le page et al., observed that increased expression of SATB2 in these tissues was 
associated with a higher over survival rate 118. Another study conducted by Dragonmir et al., 
observed that SATB2 had both high sensitivity and specificity when investigating cancers of 
unknown origin 198. Positive SATB2 expression within the tumour tissue was able to confirm 
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the colon as the origin of the cancer 198. Interestingly, SATB2 has been implicated as an 
upstream regulatory gene in endometrial leiomyomas (fibroids) 199. Abnormal SATB2 
expression is associated with the onset and development of endometrial leiomyomas through 
dysregulation of downstream genes associated with WNT/catenin, TGF-b, growth factor and 
retinoic acid signalling 199. Previous studies have found that women that develop these 
endometrial leiomyomas have a 2-3 fold increased risk of developing endometrial sarcomas 200 
and adenocarcinomas 201. The potential mechanism of SATB2 in LNG resistance can be seen 











Figure 25: Possible mechanism of LNG resistance based on previous studies  
HE4 202, KLF4 173 and FOXO1 203 all inhibit an aspect of MAPK pathway signalling. MAPK signalling leads to an 
increase in cell growth and survival 193, an increase in SATB2 expression 204 and an increase in progesterone 
receptor expression 177, 178. The WNT pathway positively induces MAPK signalling 205, however, WNT pathway 
signalling is inhibited by KLF4 172, 206, SOX17 188 and SATB2 199. KLF4 increases FOXO1 expression 179. The potential 
down regulation in MAPK signalling could lead to a decrease in PR receptor expression, which leads to decreased 
sensitivity to LNG (the main active drug in the Mirena®) and therefore, lead to non-response to the Mirena®. 







4.14 Conclusive comments on potential biomarkers  
Overall, the hypothesis “mRNA expression of key genes analysed in LNG resistant cells will 
differ from those found in LNG sensitive cells” can be accepted. In the current study, 
upregulation of CRISPLD1, SOX17 and ANO1 in LNG resistant cell lines supports previous 
findings from Li et al., 6 leading to these three upregulations being conserved across three 
different type I early stage endometrial cancer cell lines. This is an important finding as it gives 
these genes more potential to be predictive biomarkers. The findings of the current study also 
support observations made by Orbo et al., and Behrouzi et al., 82, 106 who identified low HE4 
expression to be associated with a positive response to the Mirena®, again, making this gene a 
strong potential biomarker candidate. This is the first time KLF4 and SATB2 have been 
investigated in the context of predictive biomarkers for EC treatment and therefore serve as 
novel potential biomarkers that should be further investigated. Of note, KLF4 appears to be a 
very strong potential biomarker due to its increase in expression in LNGR cells conserved across 
both immortalised cell lines and all three primary cultures. Overall, the ΔCt mRNA expression 
of these genes should be further analysed to determine if they can serve as predictive biomarkers 
that can be used clinically.  
4.15 Limitations of the current study 
4.14.1 Limitations of resistant cell lines 
The high-level laboratory model of resistance adopted in the current study was the most 
appropriate method for this project, however, the level of resistance obtained in the short time 
frame was on the lower side of resistance (6-fold increase (MFE296R) and 8-fold (MFE319R)) 
increase in IC50 for resistant cell lines respectively) and a relatively low level of resistance is 
described as ~8-12 fold higher than parental cell lines 120. The consequences of this for me was 
a less stable level of resistance, which led to high levels of variations in the behavioural profile 
analysis.  
It is important to note that there may be differences between induced resistance, developed in 
the laboratory, and spontaneous resistance, which occurs in patients that are intrinsically 
resistant to the Mirena®. Because of this, the pathways implicated in acquired resistance after 
prolonged treatment could differ from pathways altered resistance in drug naïve cells. This is 
why it is important to first identify potential markers using a high level laboratory model, and 
then to validate those findings in women treated with the Mirena® where the clinical outcome 
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of those patients is known, and upregulation or downregulation of certain genes can be critically 
analysed.  
4.14.2 Limitations of behavioural analysis 
The methods assumed for the behavioural analysis of resistant cell lines are high throughput 
and well documented in the literature, allowing me to compare methodology and results to other 
examples in the literature. However, due to being a 2D monolayer model, these assays do not 
represent what would occur physiologically, due to the lack of effect of both gravity and other 
surrounding tissues. This can lead the assays to lack predictivity 120. The 3D tumour spheroid 
invasion protocol used however serves as a better physiological representation due to the 3D 
nature of the cells themselves and the integration these cells have with ECM proteins. However, 
this was a difficult protocol to optimise and was more time consuming. It was also difficult to 
maintain the size of spheroids across both cell lines and resistant/sensitive subtypes leading to 
differing growth rates of the spheroids leading to results that may lack accuracy. Alongside this, 
it is also difficult to determine if the spheroid growth was achieved from the proliferation of the 
cells or from invasion into the ECM 120.  
4.14.3 Limitations of RT-qPCR analysis 
RT-qPCR remains the most sensitive technique for the detection of often-rare mRNA targets 
168. However, one limitation of this procedure was the non-detection of mRNA expression in 
some LNG sensitive and LNG resistant cell lines. Because the RT-qPCR procedure completes 
after 40 cycles, it cannot be determined that there is absolutely no expression in these cell lines, 
making it difficult to establish an accurate fold change. The use of three housekeeping genes 
was a strength of the current study, however, HSPCB was not expressed across all patient 
samples, making the normalisation against 2 housekeeping genes for the primary analysis.   
The HSPCB housekeeping gene was not expressed in one of the patient samples. Housekeeping 
genes are historically believed to be constitutively expressed in cells, making them ideal 
candidates for normalisation of RT-qPCR analysis 207, however, this was not investigated prior 
to the study, and obviously housekeeping gene HSPCB is not relevant under experimental 
conditions for the primary cell line analysis. Conflict exists around the best housekeeping genes 
to use with endometrial cancer cells. GAPDH, H3F3A, PPIA, and HPRT1 are housekeeping 
genes that have been proven to be stably expressed across 100 endometrioid endometrial cancer 
samples 208. Another study identified PSMC4, PUM1 and IPO8 as the best reference genes in 
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type I EC and UBC, MRPL19, PGK1 and PPIA as the best reference genes in type II EC 209. 
The post-operative diagnosis of stage III endometrioid EC in patient GB#13 or the clear cell 
diagnosis in patient GB#16 may have led to complications of using housekeeping genes 
conventionally associated with type I EC.  RPL13A and SDHA are amongst the 10 most 
commonly used housekeeping genes, both of which are highly expressed in endometrial cells 
112, therefore were good candidates for housekeeping genes to use in the current study. Primary 
cell analysis should be further optimised using housekeeping genes from the literature as careful 
selection of reference genes is vital for reliable performance of RT-qPCR. 
A further limitation of this study is that it is a candidate based approach rather than discovery 
based. The genes investigated in the current study were chosen due to being previously 
implicated in progesterone resistance or other tumorigenic pathways of EC.  A Discovery based 
approach would be to do whole transcriptome sequencing on LNG resistant and LNG sensitive 
cells and compare the DEGs between them 210. This information would be more efficacious in 
identifying novel targets that have not been previously described in the literature, however is 
very expensive and time consuming, out of the scope for this pilot study.  
Also of note is that RT-qPCR can only quantify the mRNA from within the cells themselves, 
and not from RNA released from the cells. While this information is sufficient for primary 
biomarker analysis, when looking at how these biomarkers could be utilised clinically, a 
minimally invasive sampling approach, such as a blood test is desirable over a tissue biopsy. 
Because of this, it would be beneficial to also investigate the mRNA expression in mRNA 
released from the tumour cells. These may prove to be more specific to the tumour itself, and 
easier to isolate from patient blood.  
4.15 Future Directions  
As mentioned, a limitation of this study is the development of a high-level laboratory model of 
resistance. While this type of resistance model is ideal for the current pilot study, development 
of a clinically relevant model to mimic the conditions the patients will undergo when being 
treated with the Mirena® 120 would be beneficial in future studies. The concentration of LNG 
released from the Mirena® per 24h is around 1000 times lower than the concentration of LNG 
used to treat the cells daily. These small concentrations of LNG are released from the Mirena® 
daily and decrease over time. It would be beneficial to mimic these conditions in cell cultures, 
however, this would be a lengthy process that could take around 18 months to develop 120, hence 
why it was not an appropriate model for the time period given for this project.   
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Another limitation of the current study is the minimal physiological relevance it carries. The 
next step in this project would be to validate the results found this year in more clinically 
relevant models such as 3D hybrid models and patient samples 130. Validation of behavioural 
analysis and gene expression in a 3D hybrid model of endometrial cancer would assist in 
increasing the physiological relevance of this study, and can better display differential 
responses to hormones such as oestrogen 130.   This tumour model could contain primary human 
endometrial adenocarcinoma cells and cancer associated stromal cells, the separation process 
of which was optimised this year, embedded into an ECM matrix. This model can be used to 
monitor invasion, growth and the matric remodelling potential while maintaining tumour 
heterogeneity 144. These cells could also be isolated for RT-qPCR analysis to validate the results 
found in the current study. It would be interesting to investigate the effect of oestrogen on the 
cellular proliferation rate in resistant cells compared to controls. Hormone stimulation, 
including oestrogen stimulation, plays a vital role in the regulation of the cell cycle, therefore, 
unsurprisingly, dysregulation of hormone signalling is implicated in many cancers, including 
EC 136. Stimulating the resistant and control cells while measuring proliferation may give rise 
to different rates of proliferation as the control cells will have uninterrupted growth signals 
from oestrogen, while the LNG in the treated cells should assist in controlling and potentially 
attenuating the oestrogenic response of the cells. While these results are important for the 
establishment of a stable resistant cell line and for behavioural characterisation of LNG resistant 
cells in vitro, as this stage, it lacks physiological relevance.  
It will be important to identify the most efficient way to measure predictive biomarkers 
clinically. This will involve identification of the limits of sensitivity and specificity for the 
detection methods being investigated, enabling the best method for biomarker testing can be 
ascertained. This will be done through RNA analysis of extracellular vesicles (EVs) released 
from tumour cells 211. EVs are specific to tumour cells and therefore, encapsulate various kinds 
of molecules, such as proteins and RNAs that are specific to the tumour and contribute to cancer 
malignancy 212. Due to being released into systemic circulation, isolation of EVs could serve as 
a non-invasive, clinically useful biomarker detection method 212. Enzyme-linked 
Immunosorbent Assay (ELISA) could also be utilised to detect the presence of proteins in 
patient serum samples and immunohistochemistry to measure the expression of these key 
proteins in patient samples cut from FFPE blocks. IHC can then be used to measure protein 
expression of the key genes in the tumour biopsies from patients treated with the Mirena®.  
This will assist in determining if the mRNA expression of the key genes in tumour cells or 
associated EVs, correlates with the respective protein levels in the blood. If a correlation is 
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found, it would mean that a liquid biopsy could serve as a good indication of protein expression 
in the tumour, again, serving as a non-invasive clinically useful biomarker detection method 
compared to pipelle biopsy, which is an invasive procedure.  
Whilst identifying the best approach for clinical detection, expression of the predictive 
biomarkers identified in the current study can be validated in women treated with the Mirena®. 
Having a cohort of women undergoing Mirena treatment for hyperplasia and early-stage EC 
would allow for the analysis of primary end points (response or non-response), and stratification 
according to clinicopathological patient information. This will allow for the identification of 
clinically relevant independent biomarkers that can response to the Mirena®.  
4.16 Clinical implications 
With increasing rates of EC in Aotearoa, particularly in younger premenopausal women, and 
women with high BMIs 3, 4, alternative non-invasive and fertility sparing treatments are 
necessary for these women.  
Currently, the absence of predictive biomarkers limits the certainty of recommendation of the 
Mirena® 50.  Surgery has been proven to be associated with a high cure rate and low morbidity 
rate when treating EC, particularly in early stages 95, making it the standardised treatment of 
EC. Being able to test for expression of specific predictive biomarkers prior to treatment 
through either blood or tissue analysis, would ensure that women are not exposed to further risk 
through the use of conservative Mirena® treatment instead of surgery. If that risk could be 
eliminated, then the Mirena® may not only be a first line treatment for inoperable women, but 
for all women who wish to preserve their uterus.  
As of November 2018, PHARMAC has announced that the Mirena® will be fully funded and 
previous restrictions on access will be lifted. Pharmac estimates that a further 21,000 women 
will be able to access the devices every year 109. Subsidization was an essential step to achieving 
equality in NZ as prior to this, a self-funded Mirena® was not a common choice for Māori 
(2.5%) or Pasifika (0%) 110. A significant delay exits in accessing specialist’s appointment for 
all women with EC. 77% of women are not seen within 28 days of their first medical 
appointment, with Māori women experiencing even longer delays before any consultation 112. 
Both a predictive test using biomarkers and the Mirena® insertion can be done in the clinic, 
decreasing the time it takes to see a specialist for all diagnosed women. The ease of this form 
of treatment will decrease morbidity rates dramatically, thus, decreasing inequality in NZ. 
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4.17 Conclusion  
Recent therapeutic advances in the oncology field have been driven by the recognition of 
genetic variations between individual’s tumours and using this to identify biomarkers that can 
predict response to novel and targeted therapeutics. Additional research into pathogeic genes 
previously studied alongside identification of new ones is clearly warrented and as currently, 
there are no predictive biomarkers used clinically in relation to the Mirena® treatment. The six 
potential predictive biomarkers identified in this study for the use of the Mirena® should go on 
to be investigated in further in patient cohorts and in physiologically relevant cell culture 
models to validate the results found in the current study and determine if these potential 
biomarkers are clinically relevant. This study is the first of its nature, and the candidate 
biomarkers identified alongside the behavioural analysis of LNG resistant cells could go on to 
improve women’s outcomes and help reduce long-term morbidity associated with current 
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Appendix 1: Supplementary RT-qPCR data 
Key genes from the literature N1 N2 N3 AVERAGE 
HE4 DMSO 37.33 N/A N/A 37.33 
HE4 LNG  37.18 N/A 38.77 37.975 
ANO1 DMSO 31.27 32.84 32.84 32.31667 
ANO1 LNG 31.68 29.18 29.18 30.01333 
SH3YL1 DMSO 34.39 35.22 37.98 35.86333 
SH3YL1 LNG  33.86 33.44 37.59 34.96333 
CACNA2D3 DMSO 35.11 34.08 34.08 34.42333 
CACNA2D3 LNG  33.34 31.36 31.36 32.02 
CRISPLD1 DMSO 35.82 N/A N/A 35.82 
CRISPLD1 LNG 35.89 35.84 35.69 35.80667 
FOXO1 DMSO 25.05 25.3 25.11 25.15333 
FOXO1 LNG 23.73 22.42 22.98 23.04333 
CGNL1 DMSO 29.34 35.33 34.12 32.93 
CGNL1 LNG 27.39 29.16 29.72 28.75667 
DACH1 DMSO 31.24 N/A N/A 31.24 
DACH1 LNG 28.15 35.36 35.3 32.93667 
ER DMSO 33.32 33.47 37.49 34.76 
ER LNG 31.46 34.09 34.68 33.41 
PR DMSO  34.95 35.29 34.9 35.04667 
PR LNG 31.45 32.47 31.3 31.74 
RUNDC3B DMSO 33.37 34.90 35.54 34.60333 
RUNDC3B LNG 31.65 31.30 31.85 31.6 
KLF4 DMSO 30.72 30.55 31.51 30.92667 
KLF4 LNG 27.07 27.09 27.22 27.12667 
DKK1 DMSO 38.13 37.33 38.23 37.89667 
DKK1 LNG  37.11 37.36 37.55 37.34 
SATB2 DMSO 30.13 31.82 32.8 31.58333 
SATB2 LNG 27.18 27.61 28.55 27.78 
SOX17 DMSO N/A N/A N/A N/A 
SOX17 LNG 35.86 37.3 37.3 36.82 
Housekeeping genes N1 N2 N3 AVERAGE 
RPL13A DMSO 19.23 16.93 18.85 18.33667 
RPL13A LNG 18 17.37 17.37 17.58 
SDHA DMSO 22.37 25.89 28.98 25.74667 
SDHA LNG 22.76 22.84 30.09 25.23 
HSPCB DMSO 18.54 21.53 25.05 21.70667 
HSPCB DMSO 18.43 18.49 28.28 21.73333 
Table S1: Raw Ct values for MFE296 RT-qPCR. 
Ct values for 16 key genes are indicated in blue. Ct values for housekeeping genes are indicated in yellow. 








Key genes from the literature N1 N2 N3 AVERAGE 
HE4 DMSO 22.29 23.04 22.91 22.75 
HE4 LNG  23.37 23 22.79 23.05 
ANO1 DMSO 28.42 32.04 32.04 30.83 
ANO1 LNG 29.71 31.19 31.19 30.70 
SH3YL1 DMSO 33.6 33.6 37.63 34.94 
SH3YL1 LNG  N/A 31.65 34.33 32.99 
CACNA2D3 DMSO 30.72 28.12 28.12 28.99 
CACNA2D3 LNG  33.15 28.9 28.9 30.32 
CRISPLD1 DMSO 31.57 35.06 36.67 34.43 
CRISPLD1 LNG 23.1 31.23 34.6 29.64 
FOXO1 DMSO 24.59 24.13 24.2 24.31 
FOXO1 LNG 31.81 26.16 35.85 31.27 
CGNL1 DMSO 30.77 27.88 29.12 29.26 
CGNL1 LNG 35.68 30.28 30.72 32.23 
DACH1 DMSO 34.52 28.72 28.73 30.66 
DACH1 LNG 37.45 31.65 30.78 33.29 
ER DMSO 34.27 31.54 31.58 32.46 
ER LNG 33.47 33.06 31.89 32.81 
PR DMSO  32.53 33 29.19 31.57 
PR LNG 32.64 33.88 29.24 31.92 
RUNDC3B DMSO 29.11 29.19 29.26 29.19 
RUNDC3B LNG 29.81 29.24 28.6 29.22 
KLF4 DMSO 24.83 25 23.96 24.60 
KLF4 LNG 23.99 23.88 23.47 23.78 
DKK1 DMSO 33.03 33.09 31.81 32.64 
DKK1 LNG  36.64 35.9 35.53 36.02 
SATB2 DMSO 28.11 28.69 28.13 28.31 
SATB2 LNG 28.40 28.03 28.31 28.25 
SOX17 DMSO 37.23 36.1 36.1 36.48 
SOX17 LNG 37.40 38.04 38.04 37.83 
Housekeeping genes N1 N2 N3 AVERAGE 
RPL13A DMSO 17.05 18.17 18.2 17.80667 
RPL13A LNG 18.25 18.62 18.42 18.43 
SDHA DMSO 22.38 23.53 27.71 24.54 
SDHA LNG 22.33 24.53 26.36 24.40667 
HSPCB DMSO 18.54 20.57 25.42 21.51 
HSPCB DMSO 18.43 22.01 22.67 21.03667 
 
 
Table S2: Raw Ct values for MFE319 RT-qPCR. 
Ct values for 16 key genes are indicated in blue. Ct values for housekeeping genes are indicated in 
yellow. DMSO = MFE319S, LNG = MFE319R. N = average of each biological replicate, Average = mean of 























Figure S1: Representative melt curves from the 6 significant DEGs  
A) KLF4, B) HE4, C) SOX17, D) ANO1, E) SATB2 and F) CRISPLD1. Only one peak should be observed to 
indicate specific primer binding and no contamination. (-d(RFU)/dT): negative derivative of the rate of 










Appendix 2: Morphological analysis of adenocarcinoma epithelial 














Figure S2: Morphological analysis showed no significant differences between 
adenocarcinoma epithelial cells and cancer associated stromal cells in primary cultures.  
A) GB#16 adenocarcinoma epithelial cell culture, B) GB#16 cancer associated stromal cells, C) 
GB#23 adenocarcinoma epithelial cell culture and D) GB#23 cancer associated stromal cells. 
Epithelial cells in the endometrium are columnar or cuboid shaped and develop in honeycomb 













Appendix 3: Primary kill curve analysis  
 
Figure S3: Primary GB#13 Kill Curve 
GB#13 respectively after increasing LNG doses of 0µM, 50µM, 100µM, 150µM, 200µM, 250µM, 300µM. 
30% cell viability observed at 100µM. Range of optimal treatment was seen to be between 100µM and 
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